Adhesive composition for soft tissues, adhesive composition for wound management or composition for wound dressing

FIELD: medicine.

SUBSTANCE: there are described an adhesive composition for soft tissues, an adhesive composition for wound management or a composition for wound dressing containing a monomer (A), a polymer (B) and a polymerisation inducing composition (C) containing a organoboron compound and having a viscosity of 0.4 to 75000 cP within 30 seconds after mixing the ingredients (A), (B) and (C).

EFFECT: composition possess low toxicity, low hazard and high adhesive strength, as well as excellent processing characteristics when applying and able to form a film possessing the unique properties.

16 cl, 3 dwg, 16 tbl

 

The technical field

The present invention relates to an adhesive composition for soft tissues, the adhesive composition for treatment of wounds or composition for wound dressing.

Background of invention

Were previously investigated various compositions as adhesives for soft tissue adhesives for the treatment of wounds or wound dressings, for example, compositions containing cyanoacrylate, and composition, using materials derived from organisms, such as compositions containing fibrin, and compositions containing albumin (see, for example, patent literature 1 and patent literature 2).

From the point of view of high adhesive strength, excellent compositions are compositions containing cyanoacrylate, but they have poor biocompatibility and there is a serious problem, namely, that the formaldehyde formed during the hydrolysis of processed food compositions, it has high toxicity and inhibits the healing process. In particular, in the areas that are in direct contact with the Central nervous system, blood vessels, and so on, these compositions cannot be used. Furthermore, since the curing period is extremely short, sometimes it can be difficult to use.

The compositions containing the materials derived from organisms, it is the sense of possess exceptional properties, have high biocompatibility and promote good healing, but they have low adhesive strength. Moreover, when using a composition containing as the adhesive, fibrin, etc., there is a side effect, namely, that contained in the composition of fibrin, becomes a breeding ground for bacteria, so there is a risk of infection after surgery or treatment and the risk of infection.

When the adhesive is used for skin wound or soft tissue, or when the wound is used wound dressing, usually the components are pre-mixed in a container or any containers with obtaining the composition and then the composition is applied to the surface of the soft tissue, a portion of the wound dressing or the like, considering the workability, prevention of infection, and so on, But sometimes when applying the composition on the machinability affect the structure of the composition after mixing, that is, for example, if the viscosity of the composition is too high, the composition is difficult to apply, or if the viscosity is too low, the composition spreads beyond what is necessary to the processing area. In addition, if properties such as elasticity and elongation tensile film, obtained by polymerization and curing of the adhesive, or wound dressings that are not appropriate, sometimes there is a problem of peeling of the film from the expected after application, as the skin or soft tissue are flexible elastic substrate.

As acrylic adhesives, using initiators containing organoboron compounds have low toxicity, are of low hazard and high adhesive strength, their active use in dental practice (see, for example, patent literature 3). However, for other medical applications, such as used in surgery, for adhesion to soft tissue or wound dressings, it is necessary to further improve the stability and workability of the composition between the mixing components of the composition and its application on the treated area.

References

Patent literature

Patent literature 1: Japan Patent Laid-Open Publication No. 061658/2007.

Patent literature 2: Patent Laid-Open Publication No. 051121/2006.

Patent literature 3: Patent Laid-Open Publication No. 20110913/1997.

Brief description of the invention

Technical problem

The aim of the present invention is to develop a composition which not only has low toxicity, has a low hazard and high adhesive strength, but also has exceptional machinability in the application and is capable of forming films having properties that are desirable for the adhesive for soft tissue adhesive for wound dressings or on the I treatment of wounds.

Solution

To solve the above problems were investigated compositions are preferred as adhesives for soft tissue adhesives for treatment of wounds or wound dressings. In the result, it was found that the above problems can be solved by the present invention using the adhesive composition or compositions for wound prvacki comprising a monomer, a polymer, and the specific composition of the polymerization initiator, and having after mixing these components, the viscosity within a specific range. The adhesive composition for soft tissues, the adhesive composition for treatment of wounds or composition for wound dressing of the present invention means a composition of materials that provide surface treatment of wounds in soft tissues such as skin, muscles, internal organs and blood vessels of the body, surgical wounds, wounds in accidents and so on, that is open tissues to implement the adhesion of the upper layers of the RAS or the imposition of a temporary bandage on the wound.

That is, the adhesive composition for soft tissues, the adhesive composition for treatment of wounds or composition for wound dressing of the present invention includes a monomer (A), the polymer (b) and initiate polymerization of the composition (C) containing an organoboron compound, and has Wescott 0.4 to 75000 JV within 30 seconds after mixing of components (A), (B) and (C).

The polymer (B) preferably is a mixture of polymers, which comprises polymer particles (b1) having srednevekovoi molecular weight of 30×104up to 60×104and the specific surface area of from 1.5 to 4.5 (m2/g), polymer particles (b2) having srednevekovoi molecular weight of from 5×104up to 20×104and the specific surface area of from 0.51 to 1.2 (m2/g), and polymer particles (b3) having srednevekovoi molecular weight of from 5×104up to 20×104and the specific surface area of from 0.1 to 0.5 (m2/g), and contains polymer particles (I) in an amount of from to 98 wt.% and polymer particles (b2) and polymer particles (b3) in a total amount of not less than 2 wt.% with respect to the total weight of the polymer particles (b1), (b2) and (b3), provided that the total number of polymer particles (b1), (b2) and (b3) is 100 wt.%.

The film, which is obtained from the above-mentioned adhesive compositions or compositions for wound dressings, formed after 24 hours after preparation of the composition and has a thickness of not less than 0.1 μm, a length of not less than 25 mm and a width of not less than 2 mm, preferably has a flexible elastic modulus measured at a testing speed of 2 mm/min, not more than 750 MPa and elongation at tensile strength, measured at a testing speed of 1 mm/min, not less than 5%.

The adhesive composition or the composition for R the Neva bandage may further include, for example, the polymerization inhibitor (D), UV absorbers and the plasticizer.

In the preferred embodiment of the invention, the content of the polymerization inhibitor (D) in the composition is in the range from 10 to 5000 ppm no relation to the monomer (A).

The polymerization inhibitor (D) preferably represents at least one substance selected from hydroquinone, dibutylamino, simple nanometrology ether of hydroquinone, 2,6-di-tert-butylphenol, 2,6-di-tert-butyl-p-cresol, catechin, pyragollole, benzoquinone, 2-hydroxybenzophenone, p-methoxyphenol, t-butylcatechol, butylhydroxyanisole, butylhydroxytoluene and t-butylhydroquinone.

The adhesive composition or the composition for wound dressing may further include at least one substance selected from:

anti-infective agents, antibiotics, antibacterial additives, antiviral agents, analgesics, combination analgesics, means reducing appetite, deworming drugs, anti-arthritis means, anti-asthma drugs, anticonvulsants, antidepressants, antidiuretic funds, Antidiarrhoeal funds, antihistamines, anti-inflammatory drugs, drugs against migraine, antiemetics, anti-tumor drugs, anti-parkinsonism, pretiosum what's drugs, neuroleptics, antipyretic drugs, antispasmodic funds, anticholinergics, sympathomimetic funds, cardiovascular drugs, antiarrhythmic drugs, antihypertensive drugs, diuretics, vasodilators, immunosuppressants, muscle relaxants, parasympatholytics drugs, stimulants, sedatives, tranquilizers, cholinergic funds, chemotherapeutic drugs, radiopharmaceuticals, medium, inducing the growth of bone tissue, heparin neutralizers, procoagulants, hemostatic means, xanthine derivatives, hormones, natural proteins or proteins synthesized by genetic engineering methods, polysaccharides, glycoproteins, lipoproteins, oligonucleotides, antibodies, antigens, vasopressin, analogues of vasopressin, epinephrine, selectin, promoting coagulation toxins, inhibitors of factor activation of plasminogen activators of platelets, synthetic peptides having hemostatic action,

and

fragrances such as orange oil, grapefruit oil, lemon oil, lime oil, clove oil, Wintergreen oil, peppermint oil, rectified peppermint, banana distillate, cucumber distillate, honey distillate, rose water, menthol, anethole, is alkylsalicylate, the benzaldehyde, MSG, ethylvanillin, thymol and vanillin.

In accordance with the invention, the set used as the adhesive for soft tissue adhesive for treatment of a wound or the wound dressing has a section that is placed contained in the adhesive composition or the composition for a wound dressing components of the monomer (A), the polymer (b) and containing organoboron compound initiates the polymerization of the composition (C) in the form of two or more separate sets in arbitrary combination.

The above set preferably has such a structure in which the monomer (A), the polymer (b) and initiate polymerization of the composition (C) each placed separately, and the first monomer (A) is mixed with initiate polymerization of the composition (C) containing an organoboron compound, and then mixed with the polymer (B).

When the above kit contains the polymerization inhibitor (D), the set has a section in which the components of the monomer (A), methacrylate polymer (B) initiating polymerization of the composition (C) containing an organoboron compound, and the polymerization inhibitor (D) contained in the adhesive composition for soft tissues, the adhesive composition for treatment of wounds or compositions for wound dressings, placed in two or more separate sets in arbitrary combination.

The kit may include a device that is used for applying a composition obtained by mixing the adhesive component or components for wound dressings containing components (A), (b) and (C) and if necessary additional components.

The device is, for example, swab, brush, fiber ball, cloth, sponge ball or a piece of sponge.

In the above kit may further contain an aqueous solution prior to actionnow processing, containing 1-15% by weight. citric acid and 1-5 wt%. iron chloride (III).

Advantages of the invention

The adhesive composition for soft tissues, the adhesive composition for treatment of wounds or composition for wound dressing of the present invention not only possesses low toxicity, low hazard and high adhesive strength, but also excellent machinability in EMA application and is capable of forming film, have properties that are preferred for the adhesive for soft tissue adhesive for treatment of wounds or wound dressings. When the composition is applied to the wound, aphesis can securely connect to the wound. In particular, when the composition of the present invention is applied to a wound on the top layer of skin, wound the top layer of the skin can connect to the adhesive, and after healing, the adhesive can be easily separated from the top layer of the skin.

Brief Description of Drawings

Fig.1 is a schematic illustration showing an example of a method of obtaining a sample of the films used in the examples of the present invention.

Fig.2 is a schematic illustration showing an example of the method of obtaining the evaluation sample for evaluating the adhesive strength in Examples 14A to 17A of the present invention.

Fig.3 is a schematic illustration showing an example of the method of obtaining the evaluation sample for evaluating the adhesive strength in Examples 1C, 3C, 4C and 17C of the present invention.

Description of embodiments of the invention the adhesive composition for soft tissues, the adhesive composition for treatment of wounds or composition for wound dressing of the present invention contains the monomer (A). As the monomer (a) may be any monomer without specific restrictions, which can the be polymerized by the action described below is used to initiate the polymerization of the composition (C). As the monomer (A) can be any monofunctional and polyfunctional monomer, depending on the purpose of use.

Examples of the monomers (A) include methacrylate, acrylates and other vinyl compounds.

Of these monomers, acrylates and methacrylates are preferred because of the relatively low irritation of the human body. Next can be used (meth)acrylates having in mind the acrylates and methacrylates.

From the point of view exceptional adhesive properties, preferred are monomers having an acid group.

Therefore, the preferred embodiment of the present invention is the use of a combination of (meth)acrylate (having an acid group and a monomer having an acid group, such as the monomer (A).

Examples of the monofunctional (meth)acrylate (having an acid group include:

the alkyl(meth)acrylates such as methyl(meth)acrylate, ethyl(meth)acrylate, propyl(meth)acrylate, butyl(meth)acrylate, hexyl(meth)acrylate, 2-ethylhexyl(meth)acrylate, dodecyl(meth)acrylate, lauryl(meth)acrylate, cyclohexyl(meth)acrylate, benzyl(meth)acrylate and isobornyl(meth)acrylate;

complex hydroxyanisole esters of(meth)acrylic acid such as 2-hydroxyethyl(meth)acrylate, 2-hydroxypropyl(meth)acrylate, 3-hydroxypropyl(meth)acrylate, 4-hydroxybutyl(meth) is kilat, 5-hydroxyphenyl(meth)acrylate, 6 hydroxyhexyl(meth)acrylate, 1,2-dihydroxypropyl mono(meth)acrylate, 1,3-dihydroxypropyl mono(meth)acrylate and erythritol mono(meth)acrylate;

polyalkyleneglycol mono(meth)acrylates such as diethylene glycol mono(meth)acrylate, triethylene glycol mono(meth)acrylate, polyethylene glycol mono(meth)acrylate and polypropyleneglycol mono(meth)acrylate;

monoalkyl ethers of(poly)allenglish (meth)acrylates, such as onomatology ether glycol(meth)acrylate, monotropy ether glycol(meth)acrylate, onomatology ether of diethylene glycol(meth)acrylate, onomatology ether of triethylene glycol(meth)acrylate, onomatology ether glycol(meth)acrylate and monoalkyl ether polypropyleneglycol(meth)acrylate;

complex peralkaline esters of(meth)acrylic acid, such as perforater(meth)acrylate and hexaferrites(meth)acrylate;

compounds of silane having a (meth)aryloxyalkyl group, such as γ-(meth)acrylonitrilebutadiene and γ-(meth)Acrylonitrile(trimethylsiloxy)silane; and

(meth)acrylates having a heterocyclic nucleus, such as tetrahydrofurfuryl(meth)acrylate.

Examples of the polyfunctional(meth)acrylate (having an acid group include:

poly(meth)acrylates of alcantarillas, such as ethylene glycol

di(meth)acrylate, propylene glycol di(IU is)acrylate, butyleneglycol

di(meth)acrylate, neopentylglycol di(meth)acrylate, hexyleneglycol

di(meth)acrylate, trimethylolpropane three(meth)acrylate and

pentaerythritol Tetra(meth)acrylate;

poly(meth)acrylates of polyoxyalkylene, such as diethylene glycol di(meth)acrylate, triethylene glycol di(meth)acrylate, polyethylene glycol di(meth)acrylate, dipropyleneglycol di(meth)acrylate, polypropyleneglycol di(meth)acrylate, dibutylamino di(meth)acrylate and dipentaerythritol hexa(meth)acrylate;

alicyclic or aromatic di(meth)acrylates represented by the following formula (I):

where R represents a hydrogen atom or a metal group, m and n is from 0 to 10, which may be the same or different, and R1- any one of the following:

,,,,

,,

,

,,

,;

alicyclic or aromatic epoxy di(meth)acrylates represented by the following formula (2):

where R is a hydrogen atom or a methyl group, n is from 0 to 10, and R1 - any one of the following:

,,,,

,,

,

,,

,;

and

polyfunctional(meth)acrylate having in the molecule of the urethane bond represented by the following formula (3):

where R is a hydrogen atom or a metal group, and R2- any one of the following:

,,,

,,

,

Of these(meth)acrylates are preferred monofunctional(meth)acrylates include:

the alkyl(meth)acrylates such as methyl(meth)acrylate and ethyl(meth)acrylate; hydroxyalkyl esters of(meth)acrylic acid such as 2-hydroxyethyl(meth)acrylate, 1,3-dihydroxypropyl mono(meth)acrylate and erythritol mono(meth)acrylate; and

polyethylene glycol mono(meth)acrylates, such as onomatology ether of triethylene glycol(meth)acrylate, triethylene glycol mono(meth)acrylate.

The preferred polyfunkci the national (meth)acrylates include:

di(meth)akalay having in a molecule epicreceived chain, such as triethylene glycol di(meth)acrylate and polyethylene glycol di(meth)acrylate;

compounds represented by the following formula (1):

where R is a hydrogen atom or a metal group, and m and n is from 0 to 10, which may be the same or different;

compounds represented by the following formula (2):

where R is a hydrogen atom, the metal atom or the group;

and

compounds represented by the following formula (3):

where R is a hydrogen atom or a metal band. These (meth)acrylates can be used singly or in combination of two or more types. Examples of monomers having an acid group include:

monomers having a carboxylic acid group or its anhydrous group, such as

(meth)acrylic acid and its anhydride,

1,4-di(meth)acrylonitrilebutadiene acid,

6-(meth)Acrylonitrile-1,2,6-tricarboxylic acid,

N-(meth)acryloyl-p-aminobenzoic acid,

N-(meth)acryloyl-o-aminobenzoic acid,

N-(meth)acryloyl-m-aminobenzoic acid,

N-(meth)acryloyl-5-aminosalicylic acid,

N-(meth)acryloyl-4-aminosalicylic acid,

4-(meth)aryloxyethylhalides acid and its anhydride,

4-(meth)aryloxyalkyl riolitovy acid and its anhydride,

4-(meth)ariloxipicolinamidei acid and its anhydride,

4-(meth)acrylamidoglycolate acid and its anhydride,

2-(meth)acryloyloxy acid,

3-(meth)acryloyloxy acid,

4-(meth)acryloyloxy acid,

β-(meth)acryloyloxy hydrosylate,

β-(meth)acryloyloxy gidromolot,

β-(meth)acryloyloxy hereafter,

11-(meth)acryloyloxy-1,1-undecadienal acid and

R-vinylbenzoic acid;

the monomers having the group of phosphoric acid, such as (2-(meth)aryloxides)phosphoric acid, (2-(meth)arylacetylenes)phosphoric acid and 10-(meth)acalokitesvara acid; and

the monomers having sulfonato group, such as p-styrelseledamot acid and 2-acrylamide-2-methylpropanesulfonic acid.

Of these monomers having an acid group, 4-methacryloxypropyltrimethoxy acid and its anhydride are preferred.

These monomers having the acid group may be used singly or in combination of two or more types. When using these with the acid group of the monomer adhesive composition for soft tissues, the adhesive composition for treatment of wounds or composition for wound dressings tend to have superior adhesive properties.

Preferably with KIS is now a group of the monomer is contained in an amount of 1-20 weight parts, more preferably 1-10 weight parts, even more preferably 1-8 weight parts, per 100 weight parts of the total amount of (meth)acrylia (not having an acid group and a monomer having an acid group. If this amount is outside the above range, is shown an adverse effect on the adhesive strength or biocompatibility.

The amount of monomer (A) is preferably in the range from 10 to 98,95 weight parts, more preferably from 25 to 89.5 weight parts, even more preferably 37-86 weight parts, per 100 weight parts of total monomer (A), the below-described polymer (b) and described below is used to initiate the polymerization of the composition (S).

If the amount of monomer (A) is less than the lower limit of the above range, increases the viscosity and difficulties arise when applying. If the amount of monomer (A) exceeds the upper limit of the above range, the deterioration in the adhesion strength and there is the possibility of spreading the mixture beyond the desired processing region.

In some cases, the amount of monomer (A) predpoctenie is in the range from 5 to 98,95 weight parts, more preferably from 17 to 98.5 weight parts, even more preferably 20-85 weight parts, particularly preferably 24-85 weight parts, more FAV is preferably 24 to 48 weight parts, on 100 parts by weight of the total amount of the monomer (A), the below-described polymer (b) and described below is used to initiate the polymerization of the composition (S).

If the amount of monomer (A) is less than the lower limit of the above range, increases the viscosity and difficulties arise when applying. If the amount of monomer (A) exceeds the upper limit of the above range, the adhesive strength and other properties such such as modulus, tensile strength and resistance to bending, have a tendency to deteriorate. In addition, there is the possibility of spreading the mixture beyond the desired processing region.

In the adhesive composition for soft tissues, the adhesive composition for treatment of wounds or compositions for wound dressings of the present invention may further contain a polymer (B).

Examples of the polymers (B) include methacrylate polymers, acrylate polymers, elastomers based on styrene elastomers based on vinyl chloride, elastomers based on olefins, elastomers based on polyesters, polyamide elastomers, elastomers based on urethane, ethylene/vinyl acetate copolymer and silicone polymer. These polymers can be used singly or in combination of two or more types.

Of these polymers (C) are preferred methacrylate polymers and acrylate polymers with it the key of view of homogeneity in the mixing process. Methacrylate and acrylate polymers are sometimes hereinafter referred to as "(meth)acrylate polymers".

Examples of the (meth)acrylate polymers include:

unstitched polymers, such as polymethyl(meth)acrylate, polyethylene(meth)acrylate, methyl(meth)acrylate/ethyl(meth)acrylate copolymer, methyl(meth)acrylate/butyl(meth)acrylate copolymer and a copolymer of methyl(meth)acrylate/styrene; and

crosslinked polymers such as a copolymer of methyl(meth)acrylate/ethylene glycol di(meth)acrylate, copolymer of methyl(meth)acrylate/triethylene glycol di(meth)acrylate and a copolymer of methyl(meth)acrylate and butadiene monomer.

When, among the above polymers are rubber, such as natural rubbers and synthetic rubbers, and elastomers, such as thermoplastic elastomers, by mixing them with (meth)acrylate polymer, they function as plasticizers and can increase the plasticity of the composition. Examples of synthetic rubbers include EPT (ethylene/propylene/terpolymer). Examples of thermoplastic elastomers include elastomers based on styrene elastomers based on vinyl chloride, olefin elastomers, polyester elastomers, polyamide elastomers, elastomers based on urethane, ethylene/vinyl acetate copolymer and silicone polymer.

The molecular weight of the above-mentioned elastomer is typically in the range amplit the de 1000-1000000, preferably 2000-500000. The glass transition temperature (Tg) of the elastomer is usually not higher than 20°C., preferably not higher than 0°C.

Next, in the (meth)acrylate polymers included organic or inorganic composites, in which the metal oxide or metal salt covered above unstitched polymers or crosslinked polymers.

Srednevekovoi molecular weight of the polymer, usually, (meth)acrylate polymer preferably is in the range from 1000 to 1000000, more preferably 50000-500000, even more preferably 100000-500000. The above-mentioned molecular weight is a molecular weight in terms of standard polymethyl methacrylate, as determined by gel permeation chromatography (GPC).

The polymer (B) may consist of polymer particles. When the polymer (A) composed of polymer particles, they can be polymeric particles of many kinds.

Examples of such polymer particles include polymer particles (b1) having Srednevekovoi molecular weight of 30×104up to 60×104and a specific surface area of from 1.5 to 4.5 (m2/g), polymer particles (b2) having Srednevekovoi molecular weight of from 5×104up to 20×104and a specific surface area of from 0.51 to 1.2 (m2/g), and polymer particles (b3) having Srednevekovoi molecular weight of from 5×104up to 20×104and a specific surface area of from 0.1 to 0.5 (m2 /g). The specific surface of the polymer particles (b1) is preferably in the range from 1.5 to 4.5 (m2/g), more preferably from 2.0 to 4.0 (m2/g). The specific surface of the polymer particles (b2) is preferably in the range from 0.51 to 1.2 (m2/g), more preferably from 0.6 to 1.0 (m2/g).

The specific surface of the polymer particles (b3) is preferably in the range from 0.1 to 0.5 (m2/g), more preferably from 0.2 to 0.45 (m2/g).

Volumetric average diameter of the polymer particles (b1) are usually in the range from 1 to 50 (μm), preferably, 1-40 (μm). Volumetric average diameter of the polymer particles (b2) are usually in the range from 0.1 to 40 (μm), preferably, 1-20 (μm). Volumetric average diameter of the polymer particles (b3) are usually in the range from 1 to 50 (μm), preferably 5-40 (μm).

When the polymer (B) is a polymer mixture consisting of polymer particles (b2) and polymer particles (b3), and, if necessary, the polymer particles (b1), the total number of polymer particles (b2) and polymer particles (b3) preferably is not less than 2 wt%, more preferably at least 5 wt% relative to the total weight of the polymer particles (b1), polymer particles (b2) and polymer particles (b3). Sometimes the polymer mixture consists of polymer particles (b2) and polymer particles(b3) in the total amount 100% weight. When the total number of polymer particles (b2) and polymer particles (b3) is not less than the lower limit of the above range, the polymer (C) may be homogeneous dispersed in the monomer (a) and well soluble in the monomer (A). This facilitates applying the composition to the wound or soft tissue and decreases the spread of the composition beyond the surface of the wound or soft tissue after application. When the polymer particles are polymer particles (b1), the total amount of the polymer particles (b2) and polymer particles (b3) is preferably not more than 99 wt%, more preferably not more than 95 wt%, even more preferably not more than 90 wt%. in relation to

the total weight of the polymer particles (b1), polymer particles (b2) and polymer particles (b3). When the polymer particles are polymer particles (b1), the content of the polymer particles (b1), preferably is not more than 98 wt%, more preferably not more than 95 wt%. the total weight of the polymer particles (b1), polymer particles (b2) and polymer particles (b3). The content of the polymer particles (b1) is preferably at least 1 wt%, more preferably at least 5 wt%, even more preferably at least 10 wt%. the total weight of the polymer particles (b1), polymer particles (b2) and polymer particles (b3). The amount of polymer (C) status is made, preferably, from 1 to 70 weight parts, more preferably 10-65 weight parts, even more preferably 13-65 weight parts and more preferably 13-60 weight parts per 100 weight parts of total monomer (A), polymer (b) and initiate polymerization of the composition (C). If the amount of the polymer (b) is less than the lower limit of the above range, the polymerization process becomes difficult, weakens the adhesion and, in addition, there is the possibility distribution of the mixture for the desired processing region. If the amount of the polymer (B) exceeds the upper limit of the above range, it is difficult to mixing with the monomer (A). Moreover, due to the rapid increase in viscosity becomes difficult to effect the extrusion of the mixture from the container. In addition, in some cases, there is an immediate polymerization and forms a cured product and the composition becomes uncomfortable to use as an adhesive or for treatment of wounds. When the polymer (B) is a (meth) acrylate polymer, the amount of (meth) acrylate polymer is sometimes in the range of, preferably 1-75 weight parts, more preferably 1-73 weight parts, even more preferably 10-73 weight parts, even more preferably 15-73 weight parts, particularly preferably 13-68 weight parts,most preferably 21-64 weight parts per 100 weight parts of total monomer (A), (meth) acrylate

polymer and below described initiate polymerization of the composition (S).

If the number of (meth) acrylate polymer is less than the lower limit of the above range, the adhesion strength and other properties, such as modulus, tensile strength, compressive strength and Flexural strength tend to decrease. If the number of (meth) acrylate polymer exceeds the upper limit of the above range, increases the viscosity and hampers the implementation of such procedures, as topical application and injection.

When the polymer (B) is a (meth) acrylate polymer is a mixture of polymer particles (b1), (b2) and (b3), the preferred options are the following embodiment of the invention, provided that the total amount of the polymer particles (b1), (b2) and (b3) is 100 wt%. and the total number of polymer particles (b2) and (b3) is at least 2 wt%, preferably, at least 5% of the weight.

When the amount of the polymer (b) is not less than 13 weight parts, but less than 28 weight parts, per 100 weight parts of the total amount of the monomer (A), polymer (b) and initiate polymerization of the composition (C), the number of polymer particles (b1) is preferably in the range from 10 wt%. to 95 wt%, more preferably from 15 wt%. to 95 wt%, even more preferably from 38% weight. to 95 wt%, the number is on the polymer particles (b2) is preferably, not more than 90 wt%, more preferably not more than 85 wt%, even more preferably not more than 62 wt%, and the number of polymer particles (b3) is preferably not more than 90 wt%, more preferably not more than 85 wt%, even more preferably not more than 62 wt%;

when the amount of the polymer (b) is not less than 28 weight parts, but less than 68 weight parts, per 100 weight parts of the total amount of the monomer (A), polymer (b) and initiate polymerization of the composition (C), the number of polymer particles (b1) are preferably in the range from 10 wt%. to 95 wt%, more preferably from 10 wt%. up to 80 wt%, even more preferably from 10 wt%. up to 60 wt%, the number of polymer particles (b2) is preferably not more than 90 wt%, and the number of polymer particles (b3) is preferably not more than 80% of 5 wt.,, more preferably not more than 75 wt%; and

when the amount of the polymer (b) is not less than 33 weight parts, but less than 68 weight parts, per 100 weight parts of total monomer (A), polymer (b) and initiate polymerization of the composition (C), the number of polymer particles (b1) is preferably less than 10 wt%, more preferably not more than 8 wt%, even more preferably not more than 5 wt%, the number of polymer particles (b2) is preferably not more than 100 wt%, is more preferably 20 wt%. 100% weight., and the number of polymer particles (b3) preferably is not more than 100 wt%, more preferably not more than 80 wt%.

The adhesive composition for soft tissues, the adhesive composition for treatment of wounds and composition for wound dressing of the present invention is characterized by using the below described boron compound (C1) as containing the initiator composition (C); when the boron compound is added to contain the monomer composition at a relatively early station slowly begins and continues the polymerization reaction. This contrasts with the case of using a peroxide as an initiator of polymerization, which requires a relatively long time to start polymerization even when adding a polymerization initiator, and if the polymerization reaction once it starts, the reaction proceeds quickly and ends in a relatively short period of time. To prepare the composition, which preferably is used for wounds, soft tissue, and so on, it is important to use such a polymer (B) of the present invention in such amount, as described above with respect to the monomer (A). When using such a polymer (C) can not only ensure suitability for subsequent use in a long time, but also to ensure idle state and consumer properties, which is preferable when used for wounds, soft tissue, and so on

Contained in the adhesive composition for soft tissues, the adhesive composition for treatment of wounds and compositions for wound dressings of the present invention initiate polymerization of the composition (C) contains as a main component boron compound (C1) and may contain, if necessary, aprotic solvent (C2) and alcohol (C3). As in the composition of the present invention contains initiate polymerization of the composition (C) containing, in turn, organoboron compound, the remainder of the monomer (A) tends to decrease during curing of the composition after application of the composition to the wound, soft tissue, etc., in comparison with the composition using a peroxide as an initiator of polymerization. Next part of it penetrates the epithelium and begins to cure. Therefore, the composition of the present invention is favorable for the organism.

Examples of the organoboron compounds (c1) include dealkiller, alkoxyalkyl, dealkiller and partially oxidized dealkiller.

Examples trialkylborane include trialkyls having alkyl group of 2-8 carbon atoms, such as criativo, tripropyl, triisopropyl, tribution, three-second-Bolivar, triisobutylene, triphenyl the R, trihexalon, trileptalbuy, triactive, tricyclopentadiene and tricyclohexyl. An alkyl group can be any alkyl group with a straight chain, a branched alkyl group and cycloalkyl group and contained in trialkylborane three alkyl groups may be the same or different.

Alkoxyalkyl represents, for example, monoatomically boron or dilaksanakan. More specifically, alkoxyalkyl, for example, is monoalkylation, such as butoxyethanol. Alkyl group alkoxyalkyl may be the same or different from the alkyl part of the alkoxy group.

Examples dialkylamino include diclohexal, vitaminbody. Two alkyl groups of dialkylamino may be the same or different. Two contained in dialkylamino alkyl groups may be associated with the formation of the monocyclic or bicyclic structure. Examples of such compounds include 9-borabicyclo[3.3.1]nonan.

Partially oxidized dealkiller is a partially oxidized product of the above-mentioned trialkylborane. As partially oxidized trialkylborane preferred is partially oxidized tribution. As partially oxidized trialkylborane can be used partially oxidized dealkiller received join the discharge of oxygen in the quantity preferably, from 0.3 to 0.9 mol, more preferably 0.4 to 0.6 mol per 1 mol dealkiller.

Of the above boron compounds are preferred tributive or partially oxidized tribution, more preferred is partially oxidized tribution. When used as the boron compound (C1) tributive or partially oxidized tributive improve not only the performance properties of the composition, but the composition has a suitable reactivity to moisture-containing organisms. When used as the boron compound (C1) tributive or partially oxidized tributive reaction begins and continues even in high moisture content, such as the body, so that the monomer rarely remains on the boundary surface between the adhesive or wound with a bandage and the body, Therefore, decrease harmful to the body characteristics. Such boron compound (C1) can be used separately or in combination of two or more types.

In initiating the polymerization of the composition (C) may contain aprotic solvent (C2). So as to initiate polymerization of the composition (C) contains an aprotic solvent organoboron compound is diluted and exothermic properties vosplamenyayuschaya compounds (C1) weaken and, therefore, working with composition during transport, storage and mixing easier. When you use an extremely large amount of adhesive or large wound dressing, fast heat can be inhibited by reducing the exothermic properties, and therefore, damage to the body, which is in contact with the adhesive or wound dressing of the present invention tends to decrease. Boiling point aprotic solvent (C2) at 1 ATM. usually is in the range from 30°C to 150°C, preferably 50°C. To 120°C. If the boiling point is lower than the lower limit of the above range, aprotic solvent evaporates or volatilizes from initiating polymerization of the composition during transport or during storage, and the effect of suppressing ignition of organoboron compounds (C1) tends to decline.

If the boiling point exceeds the upper limit of the above range increases the balance of an aprotic solvent in the cured product formed from the adhesive composition or the composition for a wound dressing of the present invention, thereby decreasing the performance characteristics of the adhesive compositions of the present invention.

As the aprotic solvent (C2) is preferable to actuarial, which does not react with the boron compound (C1) and capable of forming a homogeneous solution. Examples of aprotic solvents (C2) include:

hydrocarbons, such as pentane, hexane, cyclohexane, heptane, benzene and toluene;

galoidovodorodami, such as torbenson, 1,1-dichloroethane, 1,2-dichloroethane;

ethers, such as diethyl ether, diisopropyl ether, dimethyl ether of ethylene glycol, and tetrahydrofuran;

ketones, such as acetone, methylethylketone and dietician;

and

esters such as methyl acetate, ethyl acetate and isopropylacetate. Of them, preferred are saturated aliphatic hydrocarbons such as pentane, hexane and heptane, ethers, and esters, preferred are hexane, diisopropyl ether and ethyl acetate. These aprotic solvents (C2) can be used separately or in combination of two or more types.

The content of the aprotic solvent (C2) to initiate polymerization of the composition (C) is preferably 30 to 80 weight parts per 100 weight parts of boron compound (C1).

If the content of the aprotic solvent (C2) is less than the lower limit of the above range is not achieved satisfactory effect of dilution and the effect of suppressing the heat generation or ignition is nedostate the poor. On the other hand, if the content of the aprotic solvent (C2) exceeds the upper limit of the above range, the ability to initiate polymerization of the composition (C) to initiate the polymerization becomes lower than necessary.

In initiating the polymerization of the composition (C) in addition to the aprotic solvent (C2) can optionally contain alcohol (C3). Adding to initiate polymerization of the composition (C) a small amount of alcohol (C3) can further weaken the jet action of the boron compound (C1) without reducing initiate polymerization activity, and even if the composition is brought into contact with paper, etc., on the air, inhibited the effect of fire or ignition.

Examples of alcohols (C3) include methanol, ethanol, n-propanol and its isomers, n-butanol and its isomers, n-pentanol and its isomers, n-hexanol and its isomers and n-heptanol and its isomers.

Of these alcohols (C3) are preferred alcohols with 4 or less carbon atoms, namely, methanol, ethanol, n-propanol and its isomers and n-butanol and its isomers, more preferred are ethyl alcohol and n-propanol.

These alcohols (C3) can be used separately or in combination of two or more kinds.

Alcohol content (C3) to initiate polymerization of the composition (C) is predpochtitel is about in the range from 0.2 to 5 weight parts, more preferably from 0.3 to 4.5 weight parts, even more preferably from 0.5 to 4 weight parts per 100 weight parts of boron compound (C1).

If the content of alcohol (C3) is less than the lower limit of the above range, there is provided a satisfactory dilution effect and the effect of suppressing the heat generation or ignition is insufficient. On the other hand, if the content of alcohol (C3) exceeds the upper limit of the above range, initiating reduced ability to initiate polymerization of the composition (S).

When the alcohol (C3) and aprotic solvent (C2) are used in combination, the content of the aprotic solvent (C2) initiating polymerization of the composition (C) is preferably in the range of 5-40 weight parts, more preferably 10-30 weight parts, more preferably 10 to 25 weight parts, per 100 weight parts of boron compound (C1).

If the content of the aprotic solvent (C2) is less than the lower limit of the above range on 100 parts by weight of boron compound (C1), the effect of suppressing the generation of heat or ignition is insufficient. On the other hand, if the content of the aprotic solvent (C2) exceeds the upper limit of the above range on 100 weight parts of boron with denena (C1), decreases initiating ability to initiate polymerization of the composition (S).

The number of initiating polymerization of the composition (C) is preferably in the range of from 0.05 to 20 weight parts, more preferably 0.5 to 10 weight parts, more preferably 1-3 weight parts per 100 weight parts of total monomer (A), polymer (b) and initiate polymerization of the composition (S).

If the number of initiating polymerization of the composition (C) is less than the lower limit of the above range, the difficult process of polymerization and the effect of adhesion tends to decrease. If the number of initiating polymerization of the composition (C) exceeds the upper limit of the above range, because of the dilution reduces the viscosity or there is a possibility of a negative impact on safety. In addition, with the rapid polymerization immediately formed the cured product and thus lower performance of the composition as an adhesive or for treatment of wounds.

In the adhesive composition or compositions for wound dressings if necessary, may further contain other components, as they do not render harmful influence on the operating characteristics of the composition.

As one of such other components can be specified inhibitor is olymerization (D). Examples of polymerization inhibitors (D) include compounds hydroquinone, such as hydroquinone and dibutylamine, onomatology ether of hydroquinone, phenol, such as 2,6-di-tert-butylphenol and 2,6-di-tert-butyl-p-cresol, catechin, pyragollole, benzoquinone, 2-hydroxybenzophenone, p-methoxyphenol, t-butylcatechol, butylhydroxyanisole that is equivalent and t-butylhydroquinone.

Of these, the mixture nanometrology ether of hydroquinone and 2,6-di-tert-butyl-p-cresol is preferred.

Of these polymerization inhibitors (D) sometimes are preferred monomethylamine ethers of hydroquinone from the point of view of their good stability.

The above-mentioned polymerization inhibitors (D) can be used individually or in combination of two or more types.

When you add a polymerization inhibitor (D), then its amount is preferably in the range of 10-5000 ppm, more preferably 50-1000 ppm, even more preferably 50-500 ppm on the whole amount of the adhesive composition or composition for wound dressing.

It is also desirable to add a polymerization inhibitor (D) in an amount of 10-5000 ppm relative to the monomer (A).

Preparing such an adhesive composition, for example, for applying it to adherent, such as damaged during the surgery area (the damaged area is an area that does not dry because of the kind of the population of exudate from cut part), wound or soft tissue, get a composition that has excellent consumer properties, provides appropriate curing time and can more stably operate as adhesive or bandage on the wound than before. In addition, the composition is easy in handling.

Although the amount of the polymerization inhibitor (D) is the same as described above, it is more preferable to add the polymerization inhibitor (D) in an amount of 50-1000 ppm, still more preferably 5 50-500 ppm no relation to the monomer (A). Thus obtained composition may, for example, not only to operate stably at the time of application, but also effectively cured after application. If the content of the polymerization inhibitor (D) is less than the lower limit of the above range, the curing occurs immediately after mixing of the monomer (A), polymer (b) and initiate polymerization of the composition (C) and therefore, the application becomes difficult. On the other hand, if the content of the polymerization inhibitor (D) exceeds the upper limit of the above range, the ability to initiate polymerization initiating the polymerization of the composition (C) is reduced and the curing period becomes longer than necessary. Therefore, medical use of the composition becomes difficult.

As one who CSOs from other components can be specified as an absorber of ultraviolet radiation. Examples of the ultraviolet absorber of radiation include:

connection benzotriazole, such as

2-(2'-hydroxy-5'-were)benzotriazol,

2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)benzotriazol,

2-(5'-tert-butyl-2'-hydroxyphenyl)benzotriazol,

2-(2'-hydroxy-5'-(1,1,3,3-TETRAMETHYLBUTYL)phenyl)benzotriazole,

2-(3',5'-di-tert-butyl-2'-hydroxyphenyl)-5-chlorobenzotriazol,

2-(3'-tert-butyl-2'-hydroxy-5'-were)-5-chlorobenzotriazol,

2-(3'-sec-butyl-5'-tert-butyl-2'-hydroxyphenyl)benzotriazol,

2-(2'-hydroxy-4'-octyloxyphenyl)benzotriazole,

2-(3',5'-di-tert-amyl-2'-hydroxyphenyl)benzotriazol,

2-(3',5'-bis(α,α-dimethylbenzyl)-2'-hydroxyphenyl)benzotriazol,

2-(3'-tert-butyl-2'-hydroxy-5'-(2-octyloxyphenyl)phenyl)-5-chlorobenzotriazol,

2-(3'-tert-butyl-5'-[2-(2-ethylhexyloxy)carbonylethyl]-2'-hydroxyphenyl)-5-chlorobenzotriazol,

2-(3'-tert-butyl-2 hydroxy-5'-(2-methoxycarbonylethyl)phenyl)-5-chlorobenzotriazol,

2-(3'-tert-butyl-2'-hydroxy-5'-(2-methoxycarbonylethyl)phenyl)benzotriazole,

2-(3'-tert-butyl-2'-hydroxy-5'-(2-octyloxyphenyl)phenyl)benzotriazol,

2-(3'-tert-butyl-5'-[2-(2-ethylhexyloxy)carbonylethyl]-2'-hydroxyphenyl)benzotriazol,

2-(3'-dodecyl-2'-hydroxy-5'-were)benzotriazol,

a mixture of 2-(3'-tert-butyl-2'-hydroxy-5'-(2-isooctylmercaptoacetate)phenyl)

benzotriazole and 2,2'-methylene-bis[4-(1,1,3,3-TETRAMETHYLBUTYL)-6-benzotriazol-2-infenal],

the product of the interesterification reaction of 2-[3'-tert-butyl-5'-(2-methoxycarbonylethyl)-2'-hydroxyphenyl]benzotriazole with polyethylene glycol 300 and [[R-CH2CH2-COOCH2]3]2(where R is 3'-tert-butyl-4'-hydroxy-5'-2H-benzotriazol-2-ylphenyl);

compounds of benzophenone, such as

2.4 dioxybenzone, 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-octyloxybenzophenone, 2-hydroxy-4-decyloxybenzoate, 2-hydroxy-4-dodecyloxybenzoyl, 2-hydroxy-4-benzyloxybenzophenone, 2,2',4,4'-tetrahydroxybenzophenone and 2,2'-dihydroxy-4,4'-dimethoxybenzophenone; 4-tert-butylanisole, fenilsalitsilat, antifederalist, dibenzoylresorcinol, bis(4-tert-butylbenzoyl)resorcinol, benzoylation, 2,4-di-tert-butylphenyl,5-di-tert-butyl-4-hydroxybenzoate, hexadecyl 3,5-di-tert-butyl-4-hydroxybenzoate, octadecyl 3,5-di-tert-butyl-4-hydroxybenzoate, 2-methyl-4,6-di-tert-butylperbenzoate and 3,5-di-tert-butyl-4-hydroxybenzylated;

steric employed amines, such as

bis(2,2,6,6-tetramethylpiperidine)sebacina,

bis(2,2,6,6-tetramethylpiperidine)succinate,

bis(1,2,2,6,6-tetramethylpiperidine)sebacina,

bis(1,2,2,6,6-pentamethylpiperidin)-n-butyl-3,5-di-tert-butyl-4-hydroxybenzyl-malonate,

the condensation product of 1-hydroxyethyl-2,2,6,6-tetrametyl-4-hydroxypiperidine and succinic acid,

the condensation products of N,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)-diamine and 4-tert-octylamine-2,6-dichloro-1,3,5-s-triazine,

Tris(2,2,6,6-tetramethyl-4-piperidyl)nitrilotriacetate,

tetrakis(2,2,6,6-tetramethyl-4-piperidyl)-1,2,3,4-butanoate,

1,1'-(1,2-ethandiyl)bis(3,3,5,5-tetramethylpiperidine),

4-benzoyl-2,2,6,6-tetramethylpiperidine,

4 sterilox-2,2,6,6-tetramethylpiperidine,

bis(1,2,2,6,6-pentamethyl-4-piperidyl)-2-n-butyl-2-(2-hydroxy-3,5-di-tert-butylbenzyl)malonate,

3-n-octyl-7,7,9,9-tetramethyl-1,3,8-diazaspiro[4.5]decane-2,4-dione,

bis(1-octyloxy-2,2,6,6-tetramethylpiperidine)sebacina,

bis(1-octyloxy-2,2,6,6-tetramethylpiperidine)succinate,

the condensation products of N,N'-bis(2,2,6,6-tetramethyl-4-piperidyl)-diamine and 4-morpholino-2,6-dichloro-1,3,5-triazine,

the condensation products of 2-chloro-4,6-di(4-n-butylamino-2,2,6,6-tetramethylpiperidine)-1,3,5 triazine 1,2-bis(3-aminopropylene)ethane,

the condensation products of 2-chloro-4,6-di(4-n-butylamino-1,2,2,6,6-pentamethylpiperidin)-1,3,5 triazine 1,2-bis(3-aminopropylene)ethane,

8-acetyl-3-dodecyl-7,7,9,9-tetramethyl-1,3,8-diazaspiro[4.5]decane-2,4-dione,

3-dodecyl-1-(2,2,6,6-tetramethyl-4-piperidyl)pyrrolidin-2,5-dione and

3-dodecyl-1-(1,2,2,6,6-pentamethyl-4-piperidyl)pyrrolidin-2,5-dione;

connection oksamida, such as

4,4'-distractionware,

2,2'-diethoxyaniline,

2,2'-dioctyloxy-5,5'-di-tert-butylanisole,

2,2'-didodecyl-5,5'-di-tert-butylanisole,

2 ethoxy-2'-ethyloxazole,

N,N'-bis(3-dimethylaminopropyl)OK the amide,

a mixture of 2-ethoxy-5-tert-butyl-2'-atrocinerea and

2 ethoxy-2'-ethyl-5,4'-di-tert-butylaniline,

a mixture of o-methoxy - and p-methoxy-di-substituted oxanilide and

a mixture of o-ethoxy - and p-ethoxy di-substituted oxanilide;

compounds 2-(-hydroxyphenyl)-1,3,5 triazine, such as

2,4,6-Tris-(2-hydroxy-4-octyloxyphenyl)-1,3,5 triazine,

2-(2-hydroxy-4-octyloxyphenyl)-4,6-, bis(2,4-dimetilfenil)-1,3,5-triazine,

2-(2,4-dihydroxyphenyl)(2,4-dimetilfenil)-4,6-bis-1,3,5-triazine,

2,4-bis(2-hydroxy-4-proproxyphene)-6-(2,4-dimetilfenil)-1,3,5 triazine,

2-(2-hydroxy-4-octyloxyphenyl)-4,6-bis(4-were)-1,3,5-triazine,

2-(2-hydroxy-4-dodecyloxyphenyl)-4,6-bis(2,4-dimethanol)-1,3,5 triazine,

2-[2-hydroxy-4-(2-hydroxy-3-butylacetophenone)phenyl]-4,6-bis(2,4-dimetilfenil)-1,3,5-triazine,

2-[2-hydroxy-4-(2-hydroxy-3-octyloxyphenyl)phenyl]-4,6-bis(2,4-dimetilfenil)-1,3,5-triazine and

2-[4-dodecyl/tridecylamine-(2-hydroxypropyl)oxy-2-hydroxyphenyl]-4,6-bis(2,4-dimetilfenil)-1,3,5 triazine; and

the phosphites or phosphonites, such as

triphenylphosphite, diphenylacetic, phenylvaleric, Tris(nonylphenylether), trilaurylamine, trioctadecyl, distearoylphosphatidylcholine, Tris(2,4-di-tert-butylphenyl)FOSFA, diisodecylphthalate, bis(2,4-di-tert-butylphenyl)pentaerithritol, bis(2,6-di-tert-butyl-4-were)pentaerithrityl the fit, messagelistenerthreadpool, bis(2,4-di-tert-butyl-6-were)pentaerythrityl, bis(2,4,6-tri-tert-butylphenyl)pentaerythrityl, traceability, tetrakis(2,4-di-tert-butylphenyl)-4,4'-biphenylenediisocyanate, 6-isooctane-2,4,8,10-Tetra-tert-butyl-N-dibenzo[d.g]-1,3,2-dioxaphosphinan, 6-fluoro-2,4,8,10-Tetra-tert-butyl-12-methyldibenzo[d,g]-1,3,2-dioxaphosphinan, bis(2,4-di-tert-butyl-6-were)metaltastic and bis(2,4-di-tert-butyl-6-were)ethylphosphate.

As an absorber of ultraviolet radiation is preferred benzotriazole.

Adding absorber of ultraviolet radiation amount is preferably 10-1000 ppm, more preferably 100-800 ppm, no relation to the monomer (A). Adding absorber of ultraviolet radiation is reduced staining containing monomer liquid and increases the stability of the monomer during storage.

As one of the other compounds can be specified plasticizer.

Examples of plasticizers include:

esters of hydroxycarboxylic acids, such as esters of citric acid, esters of solimano acid, esters of tartaric acid, esters of malic acid, esters of lactic acid, esters of glyceric acid and esters of glycolic acid;timetravel ether trimellitic acid, dibenzoate of diethylene glycol, the diethyl ester of malonic acid, triethyl o-acetylated, benzylbutylphthalate, dibenzoate dipropyleneglycol, diethylaluminum, tributyl o-acetylated, dimethylsilicone and diesters alkalophiles.

Although the amount of the plasticizer is selected depending on the type of material, typically, the plasticizer is used in such quantity that its content ranged from 0 to 30 wt%, preferably, from 0 to 20 wt%, more preferably from 0 to 10 wt%, from all the adhesive composition or composition for wound dressing.

As one of the other compounds can be specified preservative.

Examples of preservatives include:

methylparaben, sodium methylparaben, ethylparaben, propylparaben, sodium propylparaben, butylparaben;

the cresol, chlorocresol;

resorcinol, 4-n-hexylresorcinol, 3A,4,7,7-tetrahydro-2-(trichloromethyl)thio)-1H-isoindole-1,3(2H)dione;

benzalconi chloride, sodium benzalconi chloride, benzene chloride;

benzoic acid, benzyl alcohol, pyridinium chloride, chlorbutanol, dehydrator acid, o-phenylphenol, phenol, phenethyl alcohol, potassium benzoate, potassium sorbate, sodium benzoate, sodium salt dehydracetic acid, sodium propionate, sorbic acid, thimerosal, thymol, connection finalstate, such as borate of finalstate, nitrate of finalstate and acetate f is nilrate and formaldehyde.

As other components can then be specified anti-infective funds, antibiotics, bactericidal agent, antiviral agents, analgesics, composition analgesics, anorexicskin tools, antihelminthic drugs, anti-arthritis remedies, Antiasthmatic drugs, anticonvulsants, antidepressants, antidiuretic tools, anti-diarrhoeal remedies, antihistamines, anti-inflammatory drugs, anti-migraine, anti-emetics, anti-tumor drugs, anti-Parkinson tools, antipruritic drugs, neuroleptics, Arapongas drugs, antispasmodic tools, anticholinergics, simpatomimeticescoe means, cardiovascular drugs, antiarrhythmic drugs, antihypertensive drugs, diuretics, vasodilator, immunosuppressive drugs, muscle relaxants, parasympatholytics drugs, stimulants, sedatives, tranquilizers, cholinergic tools, chemotherapeutic drugs, radiopharmaceuticals drugs, drugs that induce bone growth, heparin neutralizers static bladder, procoagulant, hemostatic agents, xanthine derivatives, hormones, natural proteins or synthesized using genetic engineering Bel and, polysaccharides, glycoproteins, lipoproteins, oligonucleotides, antibodies, antigens, vasopressin, and analogues of vasopressin, epinephrine, selectin, promoting coagulation toxins, inhibitors of factor activation of plasminogen activators of platelets and synthetic peptides having hemostatic action. Due to the content of these components, the composition of the present invention can be used as drug delivery or with the aim of regenerative medicine.

Examples of microbicides include:

elemental iodine, solid iodine polyvinylpyrrolidone, polyvinylpyrrolidone iodine;

phenolic compounds, such as tribromophenol, trichlorophenol, tetrachlorophenol, NITROPHENOL, 3-methyl-4-chlorophenol, 3,5-dimethyl-4-chlorophenol, Phenoxyethanol, dichlorophen, o-phenylphenol, m-phenylphenol, p-phenylphenol, 2-benzyl-4-chlorophenol, 2,4-dichloro-3,5-dimethylphenol, 4-hartimo, chlorophen, triclosan, phenol, 2-METHYLPHENOL, 3-METHYLPHENOL, 4-METHYLPHENOL, 4-ethylphenol, 2.4 dimethylphenol, 2.5 dimethylphenol, 3.4 dimethylphenol, 2.6 dimethylphenol, 4-n-propylene, 4-n-butylphenol, 4-n-aminophenol, 4-tert-amylphenol, 4-n-hexylphenyl, 4-n-heptylphenol, monoalkylphenol, polyalkylphenol, aromatic halophenol and ammonium salts, alkali metal salts and salts of alkaline earth metals of these substances;

silver nitrate, hexachlorophene, t is tracycline-HCl, tetracyclinee and erythromycin.

In the adhesive composition or compositions for wound dressings to expedite repair tissue as the aforementioned proteins can contain factors of development of blood vessels, basic fibroblast growth factors, epidermal growth factor, and so on

As examples of other compounds can further contain the above-mentioned flavors, such as orange oil, grapefruit oil, lemon oil, lime oil, clove oil, Wintergreen oil, peppermint oil, an alcoholic solution of peppermint, banana distillate, cucumber distillate, honey distillate, rose water, menthol, anethole, alkylsalicylate, benzaldehyde, monoglutamate sodium, ethylvanillin, thymol and vanillin.

In addition, other compounds may contain an inorganic filler, organic filler, an organic composite filler, pigment filler, etc.

Examples of inorganic fillers include:

powders of metal oxides such as zirconium oxide, bismuth oxide, titanium oxide, zinc oxide and aluminium oxide particles;

powders of metal salts, such as carbonate, bismuth, zirconium phosphate and barium sulfate;

the glass fillers, such as quartz glass, aluminum containing glass, barium-containing glass, strontium rashee glass and glass containing zirconium silicate;

the fillers that has the property of sustained release of silver; and fillers, having a slow-release fluoride.

From the point of view of forming a solid connection between the inorganic filler and monomer (A) after curing, it is preferable to use the inorganic filler is subjected to surface treatment, for example, treatment with silane or polymer coating.

These inorganic fillers may be used singly or in combination of two or more types.

As examples of other compounds can be specified x-ray contrast medium such as barium sulfate and zirconium oxide. In the present invention as a radiopaque medium Zirconia is preferred.

The adhesive composition for soft tissues, the adhesive composition for treatment of wounds or composition for wound dressing of the present invention is characterized by a viscosity of 0.4-75000 JV within 30 seconds after mixing of components (A), (b) and (C) and contained, if necessary, other components.

When the viscosity is in the above range, the composition is easily applied as an adhesive or for treatment of wounds.

From the point of view of operational properties and fluidity preferred is the viscosity in the range 0.4-10000 SP, more preferred 1-10000 SP.

The adhesive composition or the composition for a wound dressing of the present invention preferably has a viscosity of from 10 to 1000000 SP, more preferably 20-1000000 SP, even more preferably 30-800000 cf 60 seconds after mixing of components (A), (b) and (C) and contained, if necessary, other components.

When the viscosity is in the above range, the composition is easily extruded from the container as an adhesive or for wound wound dressings and has excellent performance characteristics, such as ease and simplicity in operation.

The composition of the present invention has excellent performance properties as an adhesive or for wound dressings, namely, consumer properties, such as fluidity. Using the composition of the present invention in comparison with a composition that uses peroxide as the initiator component, the doctor has more time than the time required to effect the mixing, so from this point of view, the composition of the present invention has excellent performance properties.

The film, which is obtained from the adhesive composition or the composition for a wound dressing of the present invention, is formed after 24 hours of prigot the effect of the composition, and has a thickness of not less than 1 μm (preferably not more than 1 cm), length not less than 25 mm and a width of not less than 2 mm, preferably, has a flexible elastic modulus measured at a testing speed of 2 mm/min, not more than 750 MPa, more preferably not more than 740 MPa, even more preferably not more than 730 MPa. The film, which is obtained from the composition, is formed after 24 hours after preparation of the composition and has a thickness of not less than 1 μm (preferably not more than 1 cm), length not less than 25 mm and a width of not less than 2 mm, and may preferably have a flexible elastic modulus measured at a testing speed of 2 mm/min, not more than 750 MPa, more preferably not more than 600 MPa, more preferably not more than 550 MPa.

Flexible elastic modulus of the above-mentioned cured product may preferably be not less than 100 MPa, more preferably not less than 150 MPa, more preferably not less than 200 MPa.

The film, which is obtained from the adhesive composition or the composition for a wound dressing of the present invention, is formed within 24 hours after preparation of the composition, and has a thickness of not less than 1 μm (preferably not more than 1 cm), length not less than 25 mm and a width of not less than 2 mm, preferably has an elongation at tensile, from erinne when testing speed of 1 mm/min, not less than 5%, more preferably not less than 15%, even more preferably not less than 25%.

Elongation elongation may be, preferably, not less than 5%, more preferably not less than 7%, even more preferably not less than 9%. Elongation elongation may be, preferably, not less than 30%, more preferably not less than 40%, even more preferably not less than 50%.

Obtained from the adhesive composition or the composition for a wound dressing of the present invention the cured product provides a film coating having excellent properties for soft tissue or skin, and exceptional adhesion to the skin on the areas of the bends, namely, in areas where there is a bend or flexure joint or etc.

In the present invention for the preparation of adhesive compositions or compositions for wound dressings monomer (A), the polymer (B) initiating polymerization of the composition (C) and contained if necessary components are pre-mixed and the composition can be used by applying to the wound (injury resulting from surgery, wound dressings), a soft cloth or similar

When mixing these components, the order of mixing is not limited, but preferably, with the aim of homogeneous and stable mixing a first monomer (A) is mixed with initiate polymerization of the composition (S) and then perform the mixing with the polymer (B).

When the adhesive composition or the composition for a wound dressing contains a polymerization inhibitor (D), preferably, the monomer mixture (a) and the polymerization inhibitor (D) is first mixed with initiate polymerization of the composition (C) and then mixed with the polymer (B).

Before or during curing of the adhesive composition or the composition for a wound dressing of the present invention the composition may be subjected to irradiation with electromagnetic waves such as visible light, ionizing radiation (for example, γ-rays or electron rays, with the purpose of sterilization. Sometimes it is desirable irradiation of visible light as visible light does not significantly change the conditions of curing. Sterilization can be performed by processing gas, such as dry heat, steam, ethylene oxide (EO) or hydrogen peroxide, filtering, processing liquid, autoclave sterilization, etc.

Before applying the adhesive composition or the composition for a wound dressing of the present invention to the wound, soft tissue, etc., surface wounds, soft tissue, etc., can be disinfected with a disinfectant, such as alcohol.

To improve adhesion before applying the adhesive composition or the composition for a wound dressing of the present invention to the wound, soft tissue, etc., can be performed pre-treatment is denied. The liquid pre-processing is, for example, an aqueous solution containing 1-15% by weight. citric acid and 1-5 wt%. iron chloride (III).

When applied to the wound adhesive compositions or compositions for wound dressings of the present invention, it polymerizes and solidifies with the formation of the film and therefore the composition can be used to attach to the wound or wound covering surface (that is, after connecting edges of the wound, the adhesive is applied to the surface of the wound area, adheres to the surface and hardens). In order to fix or protect the edges or the whole utverzhdenii film or maintaining or increasing the strength of adhesion during or after application of the composition to the wound using covering products such as film, sheet, paper, plaster, bandage, gauze, etc. covering These products can be capable of adhesion or have adhesiveness.

The adhesive composition or the composition for a wound dressing can be applied to the wound during or after the application of alginate dressings, hydrogel or hydropolymer on the wound.

If there are concerns that the shape or performance of the adhesive composition or the composition for a wound dressing of the present invention are changing due to preservation or storage for a long period of time, thus deteriorating the effect of this izaberete the Oia, it is possible the components comprising the monomer (A), the polymer (B) initiating polymerization of the composition (C) and contained if necessary components such as a polymerization inhibitor (D), stored in the form of set that is used as the adhesive for soft tissue adhesive for treatment of wounds or wound dressings and has two or more containers, which contained the above-mentioned components separately or divided into optimal combinations of groups, and which before use, mix with the formation of the adhesive composition or composition for wound dressing. Containers for placing components are, for example, a sealed gas-tight rubber containers to prevent evaporation or dispersion of the monomer (a) and initiate polymerization of the composition (s) or syringes with glass cylinder. Tanks for posting polymer (B) are, for example, rubber containers, with good sealing properties, or glass containers, to prevent absorption of moisture. With regard to place quantities, in some cases, placed this amount that will be spent at one time, or cases where put this number that is used for several times.

Examples of methods of storage components include the method where the components are divided into t and group, consisting of a mixture of component (a) is contained, if necessary, the components of the mixture of the component (C) is contained, if necessary, components and mixture of the component (C) is contained, if necessary, components and their subsequent storage; the method, where the components are divided into two groups consisting of a mixture of component (A) with component (b) and containing, if necessary, components, and component (C) With their subsequent storage; the method, where the components of profit into two groups, consisting of a mixture of component (A) component (b) and a mixture of the component (C) is contained, if necessary, components and their subsequent storage; the method, where the components of profit into two groups, consisting of a mixture of component (A) with component (b) and part contained, if necessary, components and mixture of the component (C) with the remainder contained, if necessary, components and their subsequent storage; the method, where the components are divided two groups, consisting of a mixture of component (a) is contained, if necessary, components and mixture of the component (C) component (C) With their subsequent storage; and the way in which the components of profit into two groups, consisting of component (A) and a mixture of the component (C) with component (C) and contained if necessary components and their subsequent storage; the method in which the components are divided into two groups consisting of a mixture of component (a) contained in part if necessary components and of the mixture of the component (C) with component (C) and the remainder is contained, if necessary, components, and their subsequent storage.

In the case when contains the polymerization inhibitor (D), examples of the storage methods include a method in which the components are divided into three groups, consisting of a mixture of component (a) is contained, if necessary, the components of the mixture of the component (C) is contained, if necessary, components and mixture of the component (C) is contained, if necessary, components and their subsequent storage; the way in which the components are divided into two groups consisting of a mixture of component (A) with component (B), component (D) and containing, if necessary, components and component (C) With their subsequent storage;

the way in which the components are divided into two groups consisting of a mixture of component (A) with component (b) and component (D) and a mixture of the component (C) is contained, if necessary, components and their subsequent storage; the way in which the components are divided into two groups consisting of a mixture of component (A) with component (B), component (D) and part contained, if necessary, components and mixture of the component (C) remain the lump contained, if necessary, components and their subsequent storage; the way in which the components are divided into two groups consisting of a mixture of component (A) with component (D) and containing, if necessary, components and mixture of the component (C) with component (C) With their subsequent storage; the way in which the components are divided into two groups consisting of a mixture of component (A) with component (D) and a mixture of the component (C) with component (C) and containing, if necessary, components and their subsequent storage; and the way in which components share group, consisting of a mixture of component (A) with component (D) and part contained, if necessary, components and mixture of the component (C) with component (C) and with the remainder contained, if necessary, components and their subsequent storage.

In addition to the above methods, when the monomer (A) use a mixture of the monomer having the acid group with a monomer having no acidic group, the components can be stored in such a way that the monomer having an acid group is not in contact with the initiating polymerization of the composition. Examples of such method include a method in which the components are divided into two groups consisting of a mixture of the monomer having an acid group, component (b) and containing, if necessary, components and mixtures of monomer not having an acid group with the components the volume (S) and their subsequent storage; the way in which the components are divided into two groups consisting of a mixture of the monomer having an acid group, component (b) and a mixture of the monomer having no acid group, component (C) and containing, if necessary, components and their subsequent storage; the way in which the components are divided into two groups consisting of a mixture of the monomer having an acid group is contained, if necessary, the components and of the mixture of the monomer having no acid group, component (b) and component (C) With their subsequent storage; and the way in which the components are divided into two groups consisting of a monomer having an acid group, and a mixture of the monomer having no acid group, component (B), component (C) and containing, if necessary, components, and their subsequent storage.

Divided into two groups of components are placed in a separate container, for example, in containers, such as syringes and containers are combined into a set, which is used as the adhesive for soft tissue adhesive for treatment of wounds or wound dressings and can be executed as a product.

The dial design is not specifically limited, provided that there is no possibility of changing the shape or performance of the components during storage and thereby causing damage to the present invention, n is preferably set is designed when the monomer (A), the polymer (b) and initiate polymerization of the composition (S) are placed separately, and the first monomer (A) is mixed with initiate polymerization of the composition (C) containing an organoboron compound, and then mixed with the polymer (B). With this design provides the adhesive composition or the composition for a wound dressing, having a more stable performance.

Examples of such sets include:

set with capacity (e.g., containers, syringes), in which the monomer (A), the polymer (b) and initiate polymerization of the composition (S) each independently are placed separately, and have the capacity (e.g., vessel or bowl for mixing) in order to extract placed in a container components and mix them; and

set with one container that has three or more chambers separated by partitions in said chambers independently placed the monomer (A), the polymer (b) and initiate polymerization of the composition (C), and having a mixer for mixing the monomer (a) and initiate polymerization of the composition (C) with polymer (B), and said components (a) and (C) pass through the bypass formed in the container by perforation or move partitions.

When set contains the polymerization inhibitor (D), the set preferably has such a con is trucchio, in which a mixture containing the monomer (a) and the polymerization inhibitor (D), the polymer (b) and initiate polymerization of the composition, each independently housed separately, and the mixture containing the monomer (a) and the polymerization inhibitor (D) is first mixed with the initiate polymerization of the composition (C) containing an organoboron compound, and then mixed with the polymer (B). Due to this structure provides the adhesive for soft tissue adhesive for treatment of wounds or wound dressing, having a more stable performance.

Examples of such sets include:

set with capacity (e.g., containers, syringes), in which a mixture containing the monomer (a) and the polymerization inhibitor (D), the polymer (b) and initiate polymerization of the composition (S) each independently are placed separately, and have the capacity (e.g., vessel or bowl for mixing) in order to extract placed in a container components and mix them; and

set with one container that has three or more chambers separated by partitions in said chambers independently placed a mixture containing the monomer (a) and the polymerization inhibitor (D), the polymer (b) and initiate polymerization of the composition (C), and having a mixer for mixing a mixture containing the monomer (a) and the polymerization inhibitor (D) and initiating polymers is a function of the composition (C) with polymer (B), with the above mixture and the specified component (S), pass through the bypass formed in the container by perforation or move partitions.

Set with one container, where the components are placed in a separate three or more cameras, requires fewer operations than the means, where the composition of the present invention separated, placed in two or more containers, usually in containers, and mixed immediately before use. In addition, this set does not contain a mixing tank, etc., and is cheap, because from the container take the required amount of composition and applied to a suitable device for use, for example a swab or sponge.

It is also possible that a device which is used for applying the adhesive composition or the composition for a wound dressing on the wound, soft tissue, etc., in advance contains part or all of initiating the polymerization of the composition (S) and the device is brought into contact with the monomer (A) or the mixture containing the monomer (a) and the polymerization inhibitor (D), the polymer (b) and contained if necessary components to obtain adhesive compositions or compositions for wound dressings of the present invention in situ and then applying it to the wound, soft fabric, etc.

Examples of such devices for applying the HDMI is tion on the wound, soft fabric, etc. include a swab, brush, fiber ball, cloth, sponge ball or a piece of sponge.

The set can include the above disinfectant liquid, such as alcohol and so on, the above-mentioned liquid for pre-treatment to improve the adhesion, the above covering the product and so on

When the components of the composition is stored in a set, they can be subjected to sterilization using electromagnetic waves such as visible light, preferably in the conditions under which the components are not modified (for example, a monomer not cures).

The adhesive composition for soft tissues, the adhesive composition for treatment of wounds or composition for wound dressing of the present invention can be used for, for example, adhesion of body tissue, for example, to cover, protect, or occlusion of wounds, for fixing (adhesion) of the graft soft tissue, hemorrhage, vascular anastomosis, vascular occlusion, bronchial anastomosis, bronchial occlusion and eye operations.

Dealing composition of the present invention directly on the available on the epidermis of the body such as the skin or mucous membrane, an open wound, it can be closed easily. In addition, the composition of the present invention can also be used for fixation of the graft in the field of transplantation is expected.

When the composition of the present invention is used for wound dressings, adhesive is not usually applied to the surface of the wound, and applied to the surface of the wound after connecting the edges of the wounds, stick to the surface and hardens. If not incised wounds, such as a scratch, crushed wound or the wound from injury, the composition may be directly applied on the damaged part to cover the wound.

Examples

Further, the present invention is described below with reference to the following examples which do not limit the invention.

Examples 1A-18A

Reagents

As the monomer (A), polymer (b) and initiate polymerization of the composition (C) in the examples you used the following compounds and compositions.

The monomer (A): 4-META/MMA, 4-methacryloxypropyltrimethoxy anhydride/methyl methacrylate (weight ratio: approximately 5%)

The polymer (C): a mixture of three kinds of the following emission spectra obtained for pure (polymetylmetacrylate) (b1)-(b3) and pigment.

The weight ratio of these components is the following: 100 weight parts of the total amount of the three kinds of emission spectra obtained for pure and pigment (b1) is contained in the number 20,03 weight parts, (b2) is contained in an amount of 62.5 parts by weight of (b3) is contained in the amount of 12.5 weight parts and the pigment else.

Molecular weight and properties (b1)-(b3) are as follows.

(b1) srednevekovoi molecular weight: 450000, sredneye the hydrated diameter of particles: 26,7 μm, specific surface area: 2.913 m2/g

(b2) srednevekovoi molecular weight: 140000, volumetric average diameter of particles: of 8.2 μm, specific surface area: 0,827 m2/g

(b3) srednevekovoi molecular weight: 140000, volumetric average diameter of particles: 24,6 μm, specific surface area: 0,371 m2/year

Volumetric average diameter of the particles of the emission spectra obtained for pure (refractive index: 1,49) was measured as follows. As the dispersion medium used special reagent - methanol brand net (refractive index: 1,33 obtained from Wako Pure Chemical IndusTpnes, Ltd.). Emission spectra obtained for pure was dispersively in the dispersion medium using an ultrasonic homogenizer for 5 minutes (output: 25 watts) and carried out the measurement at a circulation rate of 50% (100%: 65 ml/sec) using a Microtrac MT3300EXII (measuring the distribution of particle size production Microtrac Inc.).

Specific surface area was determined by absorption of gaseous nitrogen at the temperature of liquid nitrogen (77°K), using Autosorb 3 (manufactured by Quantachrome Instruments), and was measured by the BET method (method of brunauer-Emmett-teller).

Initiate polymerization of the composition (C): type TBB, namely, partially oxidized tributive: 80 weight parts, hexane: 19 weight parts ethanol: 1 weight part. Determination of the viscosity

In the sampling tube was weighed polymer (B) in accordance with the ratio of components in sm is si, described in Examples 1A-9A the following Table 1. Into the sample tube, which was weighed polymer (B) was injected monomer (a) and initiate polymerization of the composition (C), which were mixed together in another probational tube in accordance with the ratio of components in the mixture described in Examples 1A-9A the following Table 1 as above, and were mixed together at 25°C To produce adhesive compositions or compositions for wound dressings of the present invention. Within 30 seconds after receiving the measured viscosity of the composition. The viscosity at the time of receipt was not less than 0.4 JV and it was confirmed that over time the viscosity increased. The viscosity was measured using a conventional viscometer, type E (manufactured by Tokyo Keiki Inc., type EHP), at 25°C. the Results of determination are shown in Table 1. Assessment of operational properties

In the syringe with the cap in Swarovski part, was slapped in the polymer (B) in accordance with the ratio of components in the mixture described in Examples 1A-9A the following Table 1. In this syringe was injected monomer (a) and initiate polymerization of the composition (C), which were mixed together in probational tube in accordance with the ratio of components in the mixture described in Examples 1A-9A the following Table 1 as above, and were mixed together at 25°C.

Then the syringe was removed to the cap, set the nozzle having a width of 1 cm and a thickness of 1 mm, and 1 ml of the mixed composition was applied in the form of 4 cm on a plastic sheet. Operational properties were evaluated on a 5-point scale from 1 to 5. The case where the width of the applied composition was not less than 1 cm but less than 1.2 cm, was estimated at 5; the case where the width of the applied composition was not less than 1.2 cm but less than 1.4 cm, was estimated to be 4; the case where the width of the applied composition was not less than 1.4 cm, but less than 1.6 cm, was estimated at 3; the case where the width of the applied composition was not less than 1.6 cm, was estimated at 2; and the case where the application was impossible, was estimated at 1. The evaluation results are shown in Table 1.

It was confirmed that in the case of the adhesive composition or the composition for a wound dressing containing components (A), (b) and (C) and having a viscosity of 30 seconds less than 0.4 JV, the width of the applied composition was too large, and in the case of compositions having a viscosity at 30 seconds more than 75000 JV, application with a syringe was impossible.

Table 1
The adhesive composition or the composition for wound dressings (weight parts)Viscosity after 30 which after mixing (JV) Operational properties
Ave.1AThe monomer (A): 1680 mg (87,2)0,52
The polymer (In): 192,7 mg (10,0)
Initiate polymerization of the composition (C): 54 mg (2,8)
Ave.2AThe monomer (A): 1680 mg (82,4)14
The polymer (In): 305 mg (15,0)
Initiate polymerization of the composition (C): 54 mg (2,6)
Ave.3AThe monomer (A): 1680 mg (77,5)244
The polymer (In): 433,5 mg (20,0)
Initiate polymerization of the composition (C): 54 mg (2.5)
Ave.4AThe monomer (A): 1680 mg (72,7)365
The polymer (In): 578 mg (25,0)
Initiate polymerization of the composition (C): 54 mg (2,3)
Ave.5AThe monomer (A): 1680 mg (7,8) 405
The polymer (In): 743,1 mg (30,0)
Initiate polymerization of the composition (C): 54 mg (2,2)
Ave.6AThe monomer (A): 1680 mg (63,0)925
The polymer (In): 934 mg (35,0)
Initiate polymerization of the composition (C): 54 mg (2,0)
Ave.7AThe monomer (A): 1680 mg (58,1)1645
The polymer (In): 1156 mg (40,0)
Initiate polymerization of the composition (C): 54 mg (1,9)
Ave.8AThe monomer (A): 1680 mg (53,3)4725
The polymer (In): 1418,7 mg (45,0)
Initiate polymerization of the composition (C): 54 mg (1,7)
Ave.9AThe monomer (A): 1680 mg (48,4)25605
The polymer (In): 1734 mg (50,0)
Initiate polymerization of the composition (C): 54 mg (1,6)

Obtaining the polymer (approved film

In 5 ml of probatory the tube was weighed polymer (B) in accordance with the ratio of components in the mixture described in Examples 10A-13A the following Table 2. In probatory tube, which was weighed polymer (B) is injected with a mixture solution of a monomer (a) and initiate polymerization of the composition (C), which was prepared in another probational tube 1 ml in accordance with the ratio of components in the mixture described in Examples 10A-13A the following Table 1 as above, and were mixed together at 25°C for 5 seconds using a glass rod to obtain a homogeneous mixture.

The obtained adhesive composition or a composition for wound dressing was injected into the syringe and immediately filled the frame in order to prepare a sample film in accordance with the following procedure, as shown in Fig.1.

The glass plate was placed in the following order sheet RE Lumirror (trade mark) and the fluorine-rubber frame, having a thickness of 0.5 mm (inside dimension of frame: 25 mm (length)×2 mm (width)). This frame was filled with the prepared adhesive composition or a composition for wound dressing. The filling is carried out so that no air bubbles. After completing further on this imposes indicated in the data of the order sheet RE Lumirror (trade mark) and a glass plate and the four corners of the two outer plates were fixed with clamps. Then kept for 24 hours at 25°C (room temperature) and then removed the tape from the frame. If on the film surface were irregularities, the surface was cleaned waterproof abrasive sandpaper #600 to remove irregularities and was given a sample of the film. The obtained sample film had dimensions with a length of 25 mm, a width of 2 mm and a thickness of 0.5 mm.

Flexible elastic modulus (test speed: 2 mm/min) and elongation at tensile strength (test speed: 1 mm/min) of the sample film was determined using the EzTest/CE, the production of Shimadzu Corporation. Each value was measured as the average value for the four samples of the films. The evaluation results are shown in Table 2.

Table 2
The adhesive composition or the composition for wound dressings (weight parts)The modulus of elasticity MPaElongation(%)
Ave. 10AThe monomer (A): 2637 mg (84,0)31059
The polymer (In): 414 mg (13,2)
Initiate polymerization of the composition (C): 88 mg (2,8)
Ave.11AThe monomer (A): 1473 mg (70,8)36060
The polymer (In): 525 mg (25,2)
Initiate polymerization of the composition (C): 83 mg (4,0)
Ave.12AThe monomer (A): 586 mg (66,6)42030
The polymer (In): 262 mg (29,7)
Initiate polymerization of the composition (C): 33 mg (3,7)
Ave.13AThe monomer (A): 586 mg (51,2)54026
The polymer (In): 525 mg (45,9)
Initiate polymerization of the composition (C): 33 mg (2,9)

Examples 14A-17A(evaluation of adhesion strength using skin yucatán dwarf pigs (YMP)

A 5 ml sample tube was weighed polymer (B) in accordance with the ratio of components in the mixture described in Examples 14A-17A following Table 3. In this sample tube was introduced a mixture of monomer (a) and initiate polymerization of the composition (C), which was prepared in another sample tube 1 ml in accordance with the ratio of the compound is in a mixture, described in Examples 14A-17A following Table 3 similarly to the above and mixed together at 25°C for 5 seconds using a glass rod to obtain a homogeneous mixture.

The resulting composition was injected into the syringe and prepare a sample for evaluation of adhesive strength in accordance with the following procedure, as shown in Fig.2. The glass plate overlay sheet RE Lumirror (trade mark), YMP skin 2 cm × 2 cm, which was clipped adipose tissue and which was degreased with 70% aqueous ethanol (upper side: the epidermis), and the sheet fluoro-rubber frame, having a thickness of 0.5 mm, which was removed a circle with a diameter of 4.8 mm (size: 18,1 mm2), and the fluorine-rubber frame filled adhesive composition or a composition for wound dressings of examples 14A-17A. The filling is carried out so that no air bubbles. After filling later on it was applied in the specified order YMP skin (upper side: the epidermis), the sheet RE Lumirror (trade mark) and a glass plate and kept for 24 hours at 25°C (room temperature) under a load of 150, Then on both sides remove the glass plate and RE lumhror (trademark) obtaining a sample for evaluation of adhesive strength. Tension (test speed: 1 mm/min) and the adhesive strength of the sample films was determined using the EzTest/CE, is proizvodstva Shimadzu Corporation. Each value was measured as the average value for the four samples of the films. The evaluation results are shown in Table 3.

td align="left"> The polymer (In): 697 mg (46,8)
Table 3
The adhesive composition or the composition for wound dressings (weight parts)Adhesive strength (kPa)
Ave.14AThe monomer (A): 1223 mg (81,5)46
The polymer (In): 237 mg (15,8)
Initiate polymerization of the composition (C): 41 mg (2,7)
Ave.15AThe monomer (A): 1071 mg(71,4)91
The polymer (In): 381 mg(25,4)
Initiate polymerization of the composition (C): 48 mg (3,2)
Ave.16AThe monomer (A): 885 mg (81,5)114
The polymer (In): 605 mg (39,8)
Initiate polymerization of the composition (C): 30 mg (2,0)
Ave.17AThe monomer (A): 763 mg (51,2)93
Initiate polymerization of the composition (C): 30 mg (2,0)

Example 18A (assessment of tissue damage in Guinea pigs)

On the skin of the back 5-week Guinea-pig line Hartley, which were sheared and removed the hair, under anesthesia, the incision was made 3-4 cm Into the syringe, the outlet of which was closed with a lid, was slapped in the polymer (B) in accordance with the ratio of components in the mixture described in Example 18A of the following Table 4. Then into the sample tube was mixed solution of monomer (a) and initiate polymerization of the composition (C) in accordance with the ratio of components in the mixture described in Example 18A similar to the above, and the mixture was injected into the syringe, which was introduced polymer, and mixed together at 25°C. Then from the syringe, in which were placed the three components (A), (b) and (C), remove the cover, set the nozzle having an aperture width of 1 cm and a thickness of 1 mm, and within 10 seconds the mixed adhesive composition is dispensed through the nozzle orifice on the incised wound of the Guinea pig, with specified incised wound was sealed, pressing her finger.

After 30 minutes, 2 hours, 6 hours, 24 hours, 72 hours and after 168 hours after treatment investigated the extent of redness and degree distribution, then the animal from the charity mind is ruleli, cut out of the processed portion of the piece of skin 1 cm × 1 cm and fixed in formalin. Then as usual I prepared the tissue section was stained with hematoxylin-eosin and examined under an optical microscope.

As a result, no skin problems were not and redness and distribution were not found. In the study of the slice of skin inflammation caused by application of the adhesive composition or compositions for wound dressings, was not observed and damage skin tissue was not confirmed.

Table 4
The adhesive composition or the composition for wound dressings (weight parts)
Ave. 18AThe monomer (A): 192 mg (52,6)
The polymer (In): 166 mg (45,5)
Initiate polymerization of the composition (C): 7 mg (1,9)

Examples 1B-7B, Reference Examples 1B-4B

In the following examples and comparative examples used the same monomer (A), the same polymer (b) and the same initiate polymerization of the composition (C) as in the above examples. As the polymerization inhibitor (D) was used next.

The polymerization inhibitor (D): onomatology ether is of hydrochinone.

This polymerization inhibitor was dissolved in the monomer (A) in the amount described in the following Table 5, Table 6 and Table 7.

Assessment of operational properties

In the syringe, the outlet of which was closed by the lid was weighed 1156 mg (40,0 weight parts of the polymer (B). Separately, into the sample tube was weighed 1680 mg (58,1 weight parts) monomer (A), which was dissolved polymerization inhibitor (D) (monomer (A)) described in Examples 1B-3B and Reference Examples 1B-2B following Table 5, and 54 mg (1,9 weight parts) initiating polymerization of the composition (C) and mixed together, then the mixture was injected into the syringe, in which was placed the polymer (b) and was mixed at 25°C. After this the cap from the syringe, in which were placed the three components (A), (b) and (C), deleted, installed nozzle having an aperture width of 1 cm and a thickness of 1 mm, and put 1 ml of the mixed adhesive composition in the form of 4 cm on a plastic sheet. Operational properties were evaluated on a 5-point scale from 1 to 5. The case where the width of the applied composition was not less than 1 cm but less than 1.2 cm, was estimated at 5; the case where the width of the applied composition was not less than 1.2 cm but less than 1.4 cm, was estimated to be 4; the case where the width of the applied composition was not less than 1.4 cm, but less than 1.6 cm, was estimated at 3; case is th, where the width of the applied composition was not less than 1.6 cm, was estimated at 2; and the case where the application was impossible, was estimated at 1. The evaluation results are shown in Table 5.

At the time of curing

In the syringe, the outlet of which was closed by the lid was weighed 1156 mg (40,0 weight parts of the polymer (B). Separately, into the sample tube was weighed 1680 mg (58,1 weight parts) monomer (A), which was dissolved polymerization inhibitor (D) (polymer (A) described in Examples 1B-3B and Reference Examples 1B-2B following Table 5, and 54 mg (1,9 weight parts) initiating polymerization of the composition (C) and mixed together, then the mixture was injected into the syringe, in which was placed the polymer (b) and was mixed at 25°C. After this the cap from the syringe, in which were placed the three components (A), (b) and (C), deleted, installed nozzle having an aperture width of 1 cm and a thickness of 1 mm, and put 1 ml of the mixed adhesive composition in the form of 4 cm on a plastic sheet. Then, the adhesive composition was passed and referred to the fluorine-rubber block surface applied composition to investigate the time at the end of which prihvatyvaya surface (education threads) stopped. This time was estimated as the period of curing. The evaluation results are shown in Table 5.

Table 5
The polymerization inhibitor (D) (ppm)Operational propertiesCuring time (s)
Reference Etc. 1010
Ave.1B1055
Ave.2B200560
Ave.3B50003750
Reference Etc.2B1000021800

Evaluation of the stability during storage

A 5 ml sample tube was weighed 3000 mg of monomer (A), which was dissolved polymerization inhibitor (D) (polymer (A) described in Examples 4B-6B and the Reference Examples 3V-4V following Table 6, and stored in the container for 10 days at a constant temperature in the container 60°C. After 10 days of the sampling tube was opened and examined cure the content. The evaluation results with what can be found in Table 6.

Table 6
The polymerization inhibitor (D) (ppm)The storage stability
Reference Etc.3B0curing
Ave.4B100no curing
Ave.5V200no curing
Ave.6B500no curing
Reference Etc.4B10000no curing

Assessment of tissue damage in Guinea pigs

On the skin of the back 5-week Guinea-pig line Hartley, which were sheared and removed the hair, under anesthesia, the incision was made 3-4 cm Into the syringe with the cap in Swarovski part, was slapped in the polymer (B) in accordance with the ratio of components in the mixture described in Example 7B Table 7. Then the syringe was injected monomer (A), which was mixed into the sample tube with the polymerization inhibitor (D) in accordance with the ratio of components in the mixture, described in the example 7B Table 7 similarly to the above, and initiate polymerization of the composition (C) and stirred together at 25°C. Then the syringe was removed the lid, set the nozzle having an aperture width of 1 cm and a thickness of 1 mm, and put the mixed adhesive composition on the incised wound. After 30 minutes, 2 hours, 6 hours, 24 hours, 72 hours and after 168 hours after treatment was investigated properties of the skin, the presence or absence of redness and the presence or absence of the spread, after which the animal from the relief cut, cut out of the processed portion of the piece of skin 1 cm × 1 cm and fixed in formalin. Then the sample was stained with hematoxylin-eosin (H-E), in the usual way prepared tissue section and examined under an optical microscope.

As a result, no skin problems were not and redness and distribution were not found. In the study cutoff skin was not observed inflammation caused by the application of the adhesive composition, and damage to the skin tissue was not confirmed

Table 7
Adhesive composition (weight parts)
Ave.7BThe monomer (A): 166 mg (45,5)
The polymerization inhibitor (D) (monomer (A)): 200 ppm
The polymer (In): 192 mg (52,6)
Initiate polymerization of the composition (C): 7 mg (1,9)

Examples 1C-S, Comparative Examples 1C-4C

In the following examples and comparative examples used the same monomer (A) and the same initiate polymerization of the composition (C) as in the above examples. As the polymer (C) used a mixture of the above polymers (b1), (b2) and (b3) in the ratio described in the following Table 8.

Evaluation of the viscosity

In 5 ml of latex syringe with Luer lock (produced by HENKE SASS WOLF) with a plastic lid (manufactured by Osaka Chemical Co., Ltd) in Swarovski part was weighed polymer (B) in accordance with the ratio of components in the mixture described in Example 1C, Example 3, Example 4, Example 9C, the Example 10C, Example 15, Example 17C, Example 19 (C), Example 22 ° C, Example 23C and Example 27 the following Tables 8-13. In this syringe was injected monomer (a) and initiate polymerization of the composition (C), which were mixed together in 10 ml glass sample tube in accordance with the ratio of components in the mixture described in examples similar to the above, and the syringe was vigorously shaken by hand at 25°C for 20 sec for mixing and blending components contained in it. Then the cover was removed, put the needle 18G, production Terumo Corporation and in 60 CE is after preparation was measured viscosity at 35°C using a capillary viscometer (produced by NAACE, The rs150.). Viscosity during cooking was not less than 0.4 JV and it was confirmed that the viscosity has increased over time. The evaluation results are shown in Tables 8-15.

Evaluation of solubility

In 5 ml of latex syringe with Luer lock (produced by HENKE SASS WOLF) with a plastic lid (manufactured by Osaka Chemical Co., Ltd) in Swarovski part was weighed polymer (B) in accordance with the ratio of components in the mixture described in Examples 1C-31C and Comparative Examples 1C-4C the following Tables 8-15. In this syringe was injected monomer (a) and initiate polymerization of the composition (C), which were mixed together in 10 ml glass sample tube in accordance with the ratio of components in the mixture described in Examples 1C-S and Comparative Examples 1C-4C similarly to the above, and the syringe was vigorously shaken by hand at 25°C for 20 sec for mixing and blending components contained in it. After confirming the state of the mixture in the syringe by visual observation. The case when the residue of the polymer (C) was not detected, was estimated to be 3; the case when it was discovered a small residue of the polymer (C) was measured at 2; and the case when the residue of the polymer (C) was discovered in large quantities, was estimated at 1. The evaluation results are shown in Tables 8-15.

Assessment of operational properties

A 5 ml syringe (is proizvodstva HENKE SASS WOLF) with a plastic lid (manufactured by Osaka Chemical Co., Ltd) in Swarovski part was weighed polymer (B) in accordance with the ratio of components in the mixture described in Examples 1C-S and Comparative Examples 1C-4C the following Tables 8-15. In this syringe was injected monomer (a) and initiate polymerization of the composition (C), which were mixed together in the sampling tube in accordance with the mixing ratio described in examples 1C-S and Comparative Examples 1C - 4C is similar to the above, and the syringe was vigorously shaken by hand at 25°C for 20 sec for mixing the components contained in it. Then the cover was removed, set the nozzle having an aperture width of 1 cm and a thickness of 1 mm, and put 1 ml of the mixed adhesive composition in the form of 4 cm on a plastic sheet. The extrusion of the container was evaluated as follows. A case where the extrusion took place easily, was estimated at 3; case, when the extrusion was conducted with application of pressure by hand was evaluated by 2; and the case when the extrusion was not possible, was estimated at 1. The distribution of the applied composition was evaluated as follows. The case when the width of the applied composition was not less than 1 cm but less than 1.2 cm, activeline 5; case, when the width of the applied composition was not less than 1.2 cm, but less than 1.4 cm, estimated at 4; the case where the width of the applied composition was not less than 1.4 cm, but man is above 1.6 cm, assessed at 3; the case where the width of the applied composition was not less than 1.6 cm, but less than 1.8 cm, estimated at 2; the case where the width of the applied composition was not less than 1.8 cm, but less than 3 cm, was estimated at 1; and the case where the width of the applied composition was not less than 3 cm, activeline 0. The evaluation results are shown in Tables 8-15.

Obtaining polymer utverzhdenii film

In 5 ml of latex syringe with Luer lock (produced by HENKE SASS WOLF) with a plastic lid (manufactured by Osaka Chemical Co., Ltd) in Swarovski part was weighed polymer (B) in accordance with the ratio of components in the mixture described in Example 1C, Example 3, Example 4, Example 9C, the Example 10C, Example 15, Example 17C, Example 19 (C), Example 22 ° C, Example 23C, Example 27 and Example 28C following Tables 8-13. In this syringe was injected monomer (a) and initiate polymerization of the composition (C), which were mixed together in probational tube in accordance with the ratio of components in the mixture described in Example 1C, Example 3, Example 4, Example 9C, the Example 10C, Example 15, Example 17C, Example 19 (C), Example 22 ° C, Example 23C, Example 27, Example 28C same as described above and the syringe was vigorously shaken by hand at 25°C for 20 sec for mixing the components contained in it. The obtained composition was immediately filled the frame in order to prepare about ASEC film in accordance with the following procedure, as shown in Fig.1. The glass plate was placed in the following order sheet RE Lumirror (trade mark) and the fluorine-rubber frame, having a thickness of 0.5 mm (inside dimension of frame: 25 mm (length)×2 mm (width)). This frame was filled with cooked acheive composition or a composition for wound dressing. The filling is carried out so that no air bubbles. After filling later on it was applied in the specified order sheet RE Lumirror (trade mark) and a glass plate and the four corners of the two outer plates were fixed with clamps. Then kept for 24 hours at 25°C (room temperature) and then removed the tape from the frame. If on the film surface were irregularities, the surface was cleaned waterproof abrasive sandpaper #600 to remove irregularities and was given a sample of the film. The obtained sample film had dimensions with a length of 25 mm, a width of 2 mm and a thickness of 0.5 mm.

Flexible elastic modulus (test speed: 2 mm/min) and elongation at tensile strength (test speed: 1 mm/min) of the sample film was determined using an Autograph (EZ-S, production Shimadzu Corporation). The value of the bending modulus of elasticity and elongation at tensile strength was determined as the average value for the four samples of the films. The evaluation results are shown in Tables 8-13.

Evaluation of the adhesive is the second strength when using skin YMP

Test the adhesive strength was carried out according to ASTM F2255-05 using the YMP skin (obtained or Chades River Laboratories Japan, Inc.). The YMP skin thickness of 2-3 mm, which was removed layer of fat, cut into pieces of 25 mm (width)×20 mm (length) and both the surface of the skin was wiped with a paper. Then the wide side of the skin was mounted in the edges of the acrylic plate having a size of 25 mm (width)×80 mm (length) and germanou side of the skin was attached to the plate with AronAlpha(trademark obtained from TOAGOSEI CO., LTD.) so that the epidermis was on the upper side. After that, the area of the skin (epidermis) of size not less than 10 mm in length from the edge of the acrylic plate in the longitudinal direction and the lateral surface of the skin inflicted Teflon Grease (trademark) for delineating "the surface of the applied adhesive (25 mm (width)×10 mm (length))" whereby was formed adherent (substrate). This substrate is wrapped in gauze soaked in saline solution, then placed in a closed container and kept at 37°C for 30 minutes. Then 5 ml of the latex syringe with Luer lock (produced by HENKE SASS WOLF) with a plastic lid (manufactured by Osaka Chemical Co., Ltd) in Swarovski part was weighed polymer (B) in accordance with the ratio of components in the mixture described in Example 1C, Example 3, Example 4 and Example 17C following Table 8 and Table 11. In this EAP syringe is askival monomer (a) and initiate polymerization of the composition (C), which have been mixed together into the sample tube in accordance with the ratio of components in the mixture described in Example 1C, Example 3, Example 4 and Example 17C similar to the above, and the syringe was vigorously shaken by hand at 25°C for 20 sec for mixing the components contained in it through which was prepared adhesive composition or the composition for a wound dressing. The adhesive composition or the composition for wound dressing was applied on the surface of the applied adhesive (25 mm × 10 mm). It was prepared two such sample, they were placed one on another so that the surface of the applied adhesive was face to each other and kept for 1 hour under load 140, the resulting sample was wrapped in gauze soaked in saline, was placed in a container and kept at 37°C for 24 hours from receipt of sample to assess acheive strength.

Evaluate the sample was subjected to a tensile test using an Autograph (EZ-S, production Shimadzu Corporation) at a testing speed of 5 mm/minute. The average value for the four tested samples was defined as the adhesive strength. The evaluation results are shown in Table 8 and Table 11.

The overall score

The case where the points of solubility and operational properties (extrusion or Vidalia the s from the container, the distribution of applied) were each 3 or more was evaluated as AA; the case where the points of solubility and operational properties (extrusion or extrusion from the container, the spread applied) were each 2 or more was evaluated as A; the case where the points of solubility and operational properties (extrusion or extrusion from the container, the spread applied) were each 1 or more was evaluated as b; and any case where the points of solubility was 1, the case where the points of operational properties (extrusion from the container) was 1, and the case where the points of operational properties (distribution of the applied composition) was 0, was evaluated as C. the Evaluation results are shown Tables 8-15.

3
Table 8
The adhesive composition or the composition for wound dressing (the weight. part)Viscosity after 60 s after mixing (JV)SolubilityOperational propertiesMechanical propertiesThe overall score
Extrusion from the containerThe soap is important applied composition The modulus of elasticity (MPa)Elongation (%)Adhesive strength (MPa)
Ave. 1CThe monomer(A): 560 mg (80,0)1003314167442In
The polymer(In): 105 mg (15,0) (b1): 25.0% (b2): 62,5% (b3): 12,5%
Initiate polymerization of the composition (C): 35 mg (5.0)
Ave. 2CThe monomer(A): 560 mg (80,0)332And
The polymer(In): 105 mg (15,0) (b1): 75,0% (b2): 0% (b3): 25%
Initiate polymerization of the composition (C): 35 mg (5.0)
Ave. 3CThe monomer(A): 560 mg (75,3)16032438050And
The polymer(In): 149 mg (20,0) (b1): 25,0% (b2): 62,5% (b3): 12,5%
Initiate polymerization of the composition (C): 35 mg (4,7)
Ave. 4CThe monomer(A): 560 mg (70,6)1803324505075And
The polymer(In): 198 mg (25,0) (b1): 25,0% (b2): 62.5% (b3): 12.5%
Initiate polymerization of the composition (C): 35 mg (4,4)
Ave. 5CThe monomer(A): 560 mg (70,6)333AA
The polymer(In): 198 mg (25,0) (b1): 50,0% (b2): 50.5 per cent (b3) 0%
Initiate polymerization of the composition (C): 35 mg (4.4)

td align="left" morerows="2"> 4
Table 9
The adhesive composition or the composition for wound dressing (the weight. part)Viscosity after 60 s after mixing (JV)SolubilityOperational propertiesMechanical propertiesThe overall score
Extrusion from the containerThe distribution of the applied compositionThe modulus of elasticity (MPa)Elongation (%)Adhesive strength (MPa)
Ave. 6SThe monomer(A): 560 mg (70,6)335AA
The polymer (In): 18 mg (25,0) (b1): 87,5% (b2): 0% (b3): 12,5%
Initiate polymerization of the composition (C): 35 mg (4,4)
Ave.7CThe monomer(A): 560 mg (65,9)333AA
The polymer(In): 255 mg (30,0) (b1): 12,5% (b2): 87.5% (b3): 0%
Initiate polymerization of the composition (C): 35 mg (4,1)
Ave. 8SThe monomer(A): 560 mg (65,9)332And
The polymer(In): 255 mg (30,0) (b1): 12,5% (b2): 0% (b3): 87,5%
Initiate polymerization of the composition (C): 35 mg (4.1)
Ave. 9SThe monomer(A): 560 mg (65.9)390033AA
The polymer(In): 255 mg (30.0) (b1): 25.0% (b2): 75,0% (b3): 0%
Initiate polymerization of the composition (C): 35 mg (4.1)
Ave.10CThe monomer(A): 560 mg (65,9)460033470014AA
The polymer(In): 255 mg (30.0) (b1): 50.0% (b2): 0% (b3): 50,0%
Initiate polymerization of the composition (C): 35 mg (4.1)

Table 10
The adhesive composition or the composition for wound dressing (the weight. part)Viscosity after 60 s after mixing (JV)SolubilityOperational propertiesMechanical t is VA The overall score
Extrusion from the containerThe distribution of the applied compositionThe modulus of elasticity (MPa)Elongation (%)Adhesive strength (MPa)
Ave. 11SThe monomer(A): 560 mg (65.9)235And
The polymer(In): 255 mg (30.0) (b1): 75,0% (b2): 25,0% (b3): 0%
Initiate polymerization of the composition (C): 35 mg (4.1)
Ave.12SThe monomer(A): 560 mg (56.5)332And
The polymer(In): 397 mg (40.0) (b1): 0% (b2): 100% (b3): 0%
I will initiate the th polymerization composition (C): 35 mg (3.5)
Ave.13CThe monomer(A): 560 mg (65.9)331In
The polymer(In): 397 mg (40.0) (b1): 0% (b2): 0% (b3): 100%
Initiate polymerization of the composition (C): 35 mg (3.5)
Ave. 14CThe monomer(A): 560 mg (56.5)334AA
The polymer(In): 198 mg (40.0) (b1): 12.5% (b2): 87.5% (b3): 0%
Initiate polymerization of the composition (C): 35 mg (3.5)
Ave. 15CThe monomer(A): 560 mg (56.5)12800335440 68AA
The polymer(In): 397 mg (40.0) (b1): 50.0% (b2): 0% (b3): 50,0%
Initiate polymerization of the composition (C): 35 mg (3.5)

Table 11
The adhesive composition or the composition for wound dressing (the weight. part)Viscosity after 60 s after mixing (JV)SolubilityOperational propertiesMechanical propertiesThe overall score
Extrusion from the containerThe distribution of the applied compositionThe modulus of elasticity (MPa)Elongation (%)Adhesive strength (MPa)
Ave. 16CThe monomer(A) 560 mg (56,5)225 And
The polymer(C) 397 mg (40.0) (b1) 75.0% (b2) 25,0% (b3) 0%
Initiate polymerization of the composition (C) 35 mg (35)
Ave. 17CThe monomer(A) 560 mg (51.8)110003355303583AA
The polymer(C) 487 mg (45.0) (b1) 25,0% (b2) 62.5% (b3) of 12.5%
Initiate polymerization of the composition (C) 35 mg (32)
Ave. 18CThe monomer(A) 560 mg (51.8)325And
The polymer(C) 487 mg (45.0) (b1) 37.5% (b2) 0% (b3) 62.5%
Initiate polymerization of the composition (C) 35 mg (3 2)
Ave. 19 (C) The monomer (A) 560 mg (47.1)2080033554012AA
The polymer(C) 595 mg (50.0) (b1) 0% (b2) 100% (b3) 0%
Initiate polymerization of the composition (C) 35 mg (2 9)
Ave. 20SThe monomer (A) 560 mg (47.1)333AA
The polymer(C) 595 mg (50.0) (bl) 0% (b2) 50.0% (b3) 50,00%
Initiate polymerization of the composition (C) 35 mg (2,9)

Table 12
The adhesive composition or the composition for wound dressing (the weight. part)Viscosity after 60 s after mixing (JV) SolubilityOperational propertiesMechanical propertiesThe overall score
Extrusion from the containerThe distribution of the applied compositionThe modulus of elasticity (MPa)Elongation (%)Adhesive strength (MPa)
Ave. SThe monomer(A): 560 mg (47.1)332And
The polymer(In): 595 mg (50.0) (b1): 0% (b2): 0% (b3): 100%
Initiate polymerization of the composition (C): 35 mg (2.9)
Ave.22PThe monomer(A): 560 mg (47.1)1190033549016the AA
The polymer(In): 595 mg (50.0) (b1): 25.0% (b2): 12.5% (b3): 62,5%
Initiate polymerization of the composition (C): 35 mg (2,9)
Ave.23 ° CThe monomer(A): 560 mg (47.1)4170033559023-AA
The polymer(In): 595 mg (50.0) (b1): 25.0% (b2): 0% (b3): 75.0%
Initiate polymerization of the composition (C): 35 mg (2.9)
Ave.24CThe monomer(A): 560 mg (47.1)325And
The polymer(In): 595 mg (50.0) (b1): 50.0% (b2): 50.0% (b3): 0%
Initiate polymerization of the composition (C): 35 mg (2.9)
Ave.25SThe monomer(A): 560 mg (47.1)/td> 322And
The polymer(In): 595 mg (50.0) (b1): 75.0% (b2): 0% (b3): 25,0%
Initiate polymerization of the composition (C): 35 mg (2.9)

Table 13
The adhesive composition or the composition for wound dressing (the weight. part)Viscosity after 60 s after mixing (JV)SolubilityOperational propertiesMechanical propertiesThe overall score
Extrusion from the containerThe distribution of the applied compositionThe modulus of elasticity (MPa)Elongation (%)Adhesive strength (MPa)
Ave. 26C The monomer(A): 560 mg (42.4)225And
The polymer(In): 727 mg (55.0) (b1): 25.0% (b2): 75,0% (b3): 0%
Initiate polymerization of the composition (C): 35 mg (2.6)
Ave.27The monomer(A): 560 mg (37.6)3900033553019AA
The polymer(In): 893 mg (60.0) (b1): 0% (b2): 100% (b3): 0%
Initiate polymerization of the composition (C): 35 mg (2.4)
Ave. 28CThe monomer(A): 560 mg (37.6)33556010 AA
The polymer(In): 893 mg (60.0) (b1): 0% (b2): 33.3% (b3): 66.7%
Initiate polymerization of the composition (C): 35 mg (2.4)
Ave. 29SThe monomer(A): 560 mg (37.6)332And
The polymer(In): 893 mg (60.0) (b1): 0% (b2): 16.7% (b3): 83.3%
Initiate polymerization of the composition (C): 35 mg (2.4)
Ave. 30CThe monomer(A): 560 mg (32.9)325And
The polymer(In): 1105 mg (65.0) (b1): 0% (b2): 100% (b3): 0%
Initiate polymerization of the composition (C): 35 mg (2.1)

Table 14
The adhesive composition or the composition for wound dressing (the weight. part)Viscosity after 60 s after mixing (JV)SolubilityOperational propertiesMechanical propertiesThe overall score
Extrusion from the containerThe distribution of the applied compositionThe modulus of elasticity (MPa)Elongation (%)Adhesive strength (MPa)
Ave. SThe monomer(A): 560 mg (32.9)325And
The polymer(In): 1105 mg (65.0) (b1): 0% (b2): 0% (b3): 100%
Initiate polymerization of the composition (C): 35 mg (2.1)

Table 15
The adhesive composition or the composition for wound dressing (the weight. part)Viscosity after 60 s after mixing (JV)SolubilityOperational propertiesMechanical propertiesThe overall score
Extrusion from the containerThe distribution of the applied compositionThe modulus of elasticity (MPa)Elongation (%)Adhesive strength (MPa)
EUR. Ave. 1CThe monomer(A): 560 mg (84.7)330
The polymer(In): 66 mg (10.0) (b1): 25.0% (b2): 62,5% (b3): 12.5%
Initiate polymerization of the composition (C): 35 mg (5.3)
EUR. Ave.2CThe monomer(A): 560 mg (65.9) 330
The polymer(In): 255 mg (30.0) (b1): 0% (b2): 100% (b3): 0%
Initiate polymerization of the composition (C): 35 mg (4.1)
EUR. Ave.3CThe monomer(A): 560 mg (47.1)125
The polymer(In): 595 mg (50.0) (b1): 75.0% (b2): 25.0 (b3): 0%
Initiate polymerization of the composition (C): 35 mg (.9
EUR. Ave.4CThe monomer(A): 560 mg (37,6125
The polymer(In): 893 (60,0 (b1): 25.0% (b2): 62.5% (b3):12.5%
Initiate polymerization of the composition (C): 35 mg (24)

Examples 32C-34C, Comparative Example 5C

Assessment of tissue damage in rats

Male rats Crl: CD (SPF, Charles river Laboratories Japan, LTD) 11 weeks on the back of which were shorn hair was anestesiologi phenobarbital sodium and the skin disinfected alcohol cotton wool. In 5 ml of latex syringe with Luer lock (produced by HENKE SASS WOLF) with a plastic lid (manufactured by Osaka Chemical Co., Ltd) in Swarovski part was weighed polymer (B) in accordance with the ratio of components in the mixture described in Examples 32C-34C Table 16. In this syringe was injected monomer (a) and initiate polymerization of the composition (C), which were mixed together in 10 ml glass sample tube in accordance with the ratio of components in the mixture described in Examples 32C-34C Table 16 the same as the above, and the syringe was vigorously shaken by hand at 25°C for 20 sec for mixing the components contained in it. After mixing the plastic cover was removed, put the needle (18G) were removed from the syringe air and 400 µl was injected under the skin on the back (between the dermis and subcutaneous fat). In the comparative example were injected with 400 μl of cyanoacrylate skin adhesive Dermabond (trademark, manufactured Johnoson & Johnson K. K.). In quality the ve negative control was injected with 400 μl of saline.

After 72 hours or 168 hours after administration of animal relief cut part of the back skin in the area of subcutaneous injection cut without removing hair and fixed in formalin. After fixation prepared paraffin embedded sample was stained haematoxylin-eosin (H-E) (staining of lymphocytes), Congorama (Congo red) (staining eosinophils) and toluidine blue staining of mast cells) and then study under the microscope. Tissue damage was assessed on the detected pathology by the point system (0: pathology not detected 1: detected weak pathology, 2: detected average pathology, 3: found reasonable pathology, 4: detected severe pathology). The evaluation results are shown in Table 16.

In the result, it was found that when the contact Dermabond (trademark) with subcutaneous tissue, there is a moderate inflammation, but in the case of the adhesive composition or compositions for wound dressings inflammation is rarely observed. This confirms that the composition has a high security as an adhesive for skin, or wound dressings.

The results of staining
Table 16
The adhesive composition or the composition for wound dressing (the weight. part)
The dye H-EThe dye CongratDye troizinia blue
72 hour168 hour72 hour168 hour72 hour168 hour
Ave. 32CThe Monomer(A). 560 mg (75,3)222122
The polymer(In): 149 mg (20,0) (b1): 25,0% (b2): 62,5% (b3): 12,5%
Initiate polymerization of the composition (C): 35 mg (4,7)
Ave.33CThe monomer(A): 560 mg (65,9)221122
The polymer(In): 255 mg (30,0) (b1): 25,0% (b2): 62,5% (b3): 12,5%
Initiate polymerization of the composition (C). 35 mg (4,1)
Ave.34CThe monomer(A): 560 mg (56,5)121122
The polymer(In): 397 mg (40,0) (b1): 25,0% (b2): 62,5% (b3): 12,5%
Initiate polymerization of the composition (C): 35 mg (3,5)
EUR. Ave.5CDermabond333322
A negative. controlPhysiological control111122

Confirmation of healing of incised parts for example rats Male SD rats 5 weeks was anestesiologi somnophilia and then bobbed hair. On the skin at a distance of 5 mm from the xiphoid process towards the tail was made penetrating incised wound to a length of 30 mm In 5 ml of latex syringe with Luer lock (produced by HENKE SASS WOLF) with a plastic lid (manufactured by Osaka Chemical Co., td) in Swarovski part was weighed polymer (B) in accordance with the ratio of components in the mixture, described in Example 34C Table 16. In this syringe was injected monomer (a) and initiate polymerization of the composition (C), which were mixed together in 10 ml glass sample tube in accordance with the ratio of components in the mixture described in Example 34C Table 16 the same as the above, and the syringe was vigorously shaken by hand at 25°C for 20 sec for mixing the components contained in it. Then the plastic cover was removed, set the nozzle having an aperture width of 1 cm and a thickness of 1 mm using gauze stopped bleeding cut wound and then, tightly squeezing the joined surface was applied with 500 µl of adhesive. After 1 week, 2 weeks or 3 months after the treatment the animal of relief was cut, removed a piece of abdominal tissues (skin and subcutaneous tissue) with a size of 3 cm (length)×2 cm (width) and were fixed in formalin.

After fixation prepared paraffin embedded sample was stained haematoxylin-eosin (H-E), followed by assessment of the degree of healing under a microscope.

In the result, it was confirmed that the incised part, to which was applied an adhesive for leather or composition for wound dressing, did not differ from non-incised tissue and healing was successful.

A list of reference designations

11: glass plate, 12: Lumirror (trade mark), 13: fluoro-rubber R is mA (Central white part indicates the space of 25 mm (length)×2 mm (width), which is filled with an adhesive composition or a composition for wound dressings).

21: glass plate, 22: Lumiiror (trademark), 23: YMP skin (epidermis: the bottom side), 24: fluoro-rubber frame (the Central white part indicates full circle, having a diameter of 4.8 mm, filled adhesive composition or a composition for wound dressings).

31: Treated with Teflon

part 32: the YMP skin (epidermis: the upper side), 33: acrylic plate.

1. The adhesive composition forming the film, for covering wounds in soft tissues, for treatment of wounds or wound dressings comprising methacrylate (A), methacrylate polymer (b) and initiate polymerization of the composition (C) containing partially oxidized tribution, and having a viscosity of 100 to 1,000,000 SP within 60 seconds after mixing of components (A), (b) and (C), the polymer (B) is a mixture of polymers, which comprises polymer particles (b1), having srednevekovoi molecular weight of 30×104up to 60×104and the specific surface area of from 1.5 to 4.5 (m2/g), polymer particles (b2) having srednevekovoi molecular weight of from 5×104up to 20×104and the specific surface area of from 0.51 to 1.2 (m2/g), and polymer particles (b3) having srednevekovoi molecular weight of from 5×104up to 20×104and the specific surface area of from 0.1 to 0.5 (m2/g, and contains polymer particles (b1) in an amount of from 10 to 60 wt.% and polymer particles (b2) and polymer particles (b3) in a total amount of not less than 2 wt.% with respect to the total weight of the polymer particles (b1), (b2) and (b3), provided that the total number of polymer particles (b1), (b2) and (b3) is 100 wt.% and thus, the amount of the component (C) is in the range from 15 to 55 weight.h. at the rate of 100 weight.h. of the total number of methacrylate (S), polymer (b) and initiate polymerization of the composition (S).

2. Adhesive composition for covering wounds in soft tissues, for treatment of wounds and wound dressings under item 1, in which the quantity of the component (C) is in the range from 25 to 55 weight.h. at the rate of 100 weight.h. of the total number of methacrylate (S), polymer (b) and initiate polymerization of the component (C).

3. The adhesive composition forming the film, for covering wounds in soft tissues, for treatment of wounds or wound dressings under item 1, which further comprises a polymerization inhibitor (D).

4. The adhesive composition forming the film, for covering wounds in soft tissues, for treatment of wounds or wound dressings under item 3, where the concentration of the polymerization inhibitor (D) is in the range from 10 to 5000 ppm with respect to the methacrylate (A), the content of the methacrylate (A) is in the range from 5 to 98,95 weight.h., and the content of initiating polymerization of the composition (C), steriade the organoboron compound, is in the range from 0.05 to 20 weight.h., provided that the total of components (A), (b) and (C) is 100 weight.h.

5. The adhesive composition forming the film, for covering wounds in soft tissues, for treatment of wounds or wound dressings under item 3, where the polymerization inhibitor (D) preferably represents at least one substance selected from hydroquinone, dibutylamino, simple nanometrology ether of hydroquinone, 2,6-di-tert-butylphenol, 2,6-di-tert-butyl-p-cresol, catechin, pyragollole, benzoquinone, 2-hydroxybenzophenone, p-methoxyphenol, t-butylcatechol, butylhydroxyanisole, butylhydroxytoluene and t-butylhydroquinone.

6. The adhesive composition forming the film, for covering wounds in soft tissues, for treatment of wounds or wound dressings under item 1, which further includes an absorber of ultraviolet radiation.

7. The adhesive composition forming the film, for covering wounds in soft tissues, for treatment of wounds or wound dressings under item 1, which further comprises a plasticizer.

8. The adhesive composition forming the film, for covering wounds in soft tissues, for treatment of wounds or wound dressings under item 1, which further includes at least one substance selected from:
anti-infective agents, antibiotics, antibacterial additives, anti-virus tools, analge the Cove, combinations of analgesics, means reducing appetite, deworming drugs, anti-arthritis means, anti-asthma drugs, anticonvulsants, antidepressants, antidiuretic funds, Antidiarrhoeal funds, antihistamines, anti-inflammatory drugs, drugs against migraine, antiemetics, anti-tumor drugs, anti-parkinsonism, antipruritic drugs, antipsychotic drugs, antipyretic drugs, antispasmodic funds, anticholinergics, sympathomimetic funds, cardiovascular drugs, antiarrhythmic drugs, antihypertensive drugs, diuretics, vasodilators, immunosuppressants, muscle relaxants, parasympatholytics drugs, stimulants, sedatives, tranquilizers, cholinergic funds chemotherapeutic drugs, radiopharmaceuticals, medium, inducing the growth of bone tissue, heparin neutralizers, procoagulants, hemostatic means, xanthine derivatives, hormones, natural proteins or proteins synthesized by genetic engineering methods, polysaccharides, glycoproteins, lipoproteins, oligonucleotides, antibodies, antigens, vasopressin, and analogues of vasopressin, epinephrine, selectin, promoting is vagulely toxicants inhibitors of factor activation of plasminogen activators of platelets, synthetic peptides having hemostatic action and fragrances such as orange oil, grapefruit oil, lemon oil, lime oil, clove oil, Wintergreen oil, peppermint oil, rectified peppermint, banana distillate, cucumber distillate, honey distillate, rose water, menthol, anethole, alkylsalicylate, benzaldehyde, MSG, ethylvanillin, thymol and vanillin.

9. The film formed from the adhesive composition, to cover wounds in soft tissues, for treatment of wounds or wound dressings, which is obtained from the above-mentioned adhesive compositions or compositions for wound dressings under item 1, and the film obtained from the adhesive composition or the composition for a wound dressing after 24 h after preparation of the composition and has a thickness of not less than 0.1 μm, a length of not less than 25 mm and a width of not less than 2 mm, has a flexible elastic modulus measured at a testing speed of 2 mm/min, not more than 750 MPa and elongation at tensile, measured at a testing speed of 1 mm/min, not less than 5%.

10. Adhesive kit to cover wounds in soft tissues, for treatment of wounds or wound dressing, having a section that is placed contained in the adhesive composition for soft tissues, the adhesive is first composition for treatment of wounds or in the composition for a wound dressing components methacrylate (A), polymer (C) containing organoboron compound initiates the polymerization of the composition (C) under item 1, in the form of two or more separate sets in arbitrary combination.

11. Adhesive kit to cover wounds in soft tissues, for treatment of wounds or wound dressings under item 10, which is of such a construction, in which methacrylate (A), the polymer (b) and initiate polymerization of the composition (C) each placed separately, and first methacrylate (A) is mixed with initiate polymerization of the composition (C) containing an organoboron compound, and then mixed with the polymer (B).

12. Adhesive kit to cover wounds in soft tissues, for treatment of wounds or wound dressing, having a section in which the components methacrylate (A), methacrylate polymer (B) initiating polymerization of the composition (C) containing an organoboron compound, and the polymerization inhibitor (D) contained in the adhesive composition for soft tissues, the adhesive composition for treatment of wounds or compositions for wound dressings on p. 3, placed in two or more separate sets in arbitrary combination.

13. Adhesive kit to cover wounds in soft tissues, for treatment of wounds or wound dressings on p. 12 having such a structure, in which a mixture of methacrylate (a) and the polymerization inhibitor (D), the polymer (b) and the INIC is yuusei polymerization of the composition (S) each independently placed separately, and first with a mixture of methacrylate (a) and the polymerization inhibitor (D) is mixed with initiate polymerization of the composition (C) containing an organoboron compound, and then mixed with the polymer (B).

14. Adhesive kit to cover wounds in soft tissues, for treatment of wounds or wound dressings under item 13, which includes a device which is used to apply a composition obtained by mixing the adhesive component or components for wound dressings containing components (A), (b) and (C), or a composition obtained by mixing the adhesive component or components for wound dressings containing components (A), (B), (C) and (D).

15. Adhesive kit to cover wounds in soft tissues, for treatment of wounds or wound dressings on p. 14, where the device represents at least one device selected from a swab, brush, fiber ball, wipes, sponge ball or a piece of sponge.

16. Adhesive kit to cover wounds in soft tissues, for treatment of wounds or wound dressings under item 14, which further contains an aqueous solution for pre-adhesion treatment containing 1-15% wt. citric acid and 1-5 wt.% iron chloride (III).



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine. What is described is a composition for hard tissue repair containing 5 to 98.95 weight portions of a monomer (A), 1 to 75 weight portions of (meth)acrylate polymer (B) and 0.05 to 20 weight portions of a polymerisation initiating composition (C) containing an organoboron compound (c1) providing the ingredients (A), (B) and (C) total makes 100 weight portions. What is described is a kit for the hard tissue repair.

EFFECT: composition generates little setting heat and can provide for manipulations for a long period of time.

18 cl, 2 dwg, 11 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine and can be used for collection of organism's secretions. Device for collection of organism's secretions contains collection packet and adhesive pad for fixation to skin, and sad pad contains protective layer, first layer and second layer of hydrocolloidal adhesive substance, where second layer of hydrocolloidal adhesive substance, at least, partly is located between first layer of hydrocolloidal adhesive substance and protective layer. First and second layers of adhesive substance consist of continuous and discontinuous phase. Discontinuous phase of first layer of adhesive substance contains pectin, carboxymethylcellulose, gelatin, guar gum and potato starch, continuous phase of first layer of adhesive substance contains polyisobutylene, styrol block-copolymer, butyl rubber and tackifier. Discontinuous phase of second layer of adhesive substance contains carboxymethylcellulose, gelatin and guar gum, and continuous phase of second layer of adhesive substance contains polyisobutylene and styrol block-copolymer.

EFFECT: invention improves indices of tack and adhesiveness of first layer, which makes it possible to prevent passage of liquid, secreted fro body orifice through adhesive construction with preservation of low risk of irritation of skin around patient's body orifice.

11 cl, 3 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: claimed invention relates to biocompatible polyisocyanate macromer or mixture of macromers for application as glue or sealant for internal application, represented by formula: , where f equals two or more; a in the range from 1 to 5 and R1 represents , where d is in the range from 0 to 5 and c can be in the range from 1 to 100; R2 represents , where R3 represents linear or branched residue of water-soluble polymer, which forms ester bonds with R4 and urethane bonds with R1, when a equals one or more; and R4 represents linear or branched organic residue, which contains two or more carboxylate terminal groups, and x gives the number of repeating R4 and is in the range 2≤x≤6. Also described are biocompatible elastic gel, obtained by polymerisation of said macromer, composition, applicable for medicine, and method of internal wound closing.

EFFECT: creation of glue or sealant for internal application, preserving ability for manipulations and smoothing, which fills internal sinuses and empty spaces, penetrates and tightly fits cavities and pores of tissue before hardening or setting, and is biologically decomposable.

9 cl, 3 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: present invention refers to medicine, and describes a medically applicable formulation containing macromer with terminal diisocyanate groups or a mixture thereof, and oxidised cellulose. This formulation is used as an adhesive or sealer for internal application.

EFFECT: use of the described formulation improves the polymer adhesion to the substrate when excessive free water in the operation place limits the effectiveness of the adhesive.

1 cl, 2 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is described is a medical semi-synthetic adhesive bioimplant of new generation of biopolymer nanocomposites in the form of semi-synthetic polymer matrix containing a base in the form of low-molecular polyisobutylene, an excipient in the form of collapan, a binding agent in the form of castor air-oil mist lubrication; in order to improve setting of the microporous adhesive sandwich, a repetitively-pulsed laser scalpel (CO2 laser) is used intraoperatively. An upper layer hardener is a polymer adhesive strip with polyacrylamide hydrogel placed in a polymer bath.

EFFECT: medical semi-synthetic adhesive bioimplant has high adhesion characteristics.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medical equipment and may be used in producing adhesive elements for colo-, ileo- and urostomy bags and urine collection bags. The composition contains, wt %: acrylate copolymer 10-20, polyisobutylene 15-35, castor oil 10-20, hydrocolloids 20-30, and a target additive 0.1-30.

EFFECT: invention aims at preparing the adhesive polymeric composition having improved adhesion to polyolefines and natural latex, and also has a therapeutic and preventive action on skin, causes no irritations and erythemas.

4 cl, 1 tbl, 5 ex

FIELD: invention relates to medicine.

SUBSTANCE: method of agglutination of biological tissues is described herein; the method lies in smearing of the bio-degradable glue on the tissue; the glue containing liquid-hardened isocyanate-functional component is produced by interacting of: (a) the multifunctional isocyanate component and (b) multifunctional component with active hydrogen groups which includes at least 30% of the total mass of the multifunctional component with active hydrogen groups, multifunctional reagent with active hydrogen groups having the equivalent mass of less than 100; the relation of the R active hydrogen groups to the isocyanate groups can be less than 1.0.

EFFECT: agglutination of the biological tissues ensures good cosmetic result.

32 cl, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: declared invention concerns hydrogel compositions useful as a dressing material or protective agent, and for application of a wide range of active substances in relation to the skin and tissues of mucosas, such as mouth, including tooth bleaches. The faza-parted, film-forming composition containing an admixture is offered: (a) the first polymer bulking up in water, and the specified polymer is not dissolved in water at pH less than approximately 5.5, or water-soluble polymer; (b) an admixture of hydrophylic polymer and additional low-molecular polymer, capable to formation of hydrogen communications with hydrophylic polymer; (c) the second polymer bulking up in water, and the specified polymer we will not dissolve in water at all value pH; and (d) unessential active substance, in a dissolvent or in an admixture of dissolvents where the composition is exposed to separation of phases at hydration.

EFFECT: treatment of a disease state of various surfaces of a body (teeth, fingernails, skin, mucosas etc).

44 cl, 7 ex

FIELD: medicine.

SUBSTANCE: adhesive contains mixed isocyanate-pattern molecules derived from molecule reaction with number of isocyanate functional groups with the complex precursor molecules including end functional groups, chosen from the group consisting of hydroxyl group, primary amides and secondary amides. Preferably, functional groups are hydroxyl. Complex precursor molecules are biologically compatible. Precursors with number of molecule amides with number of isocyanate functional groups are biologically compatible as well. Mixed molecules preferably has average isocyanate functional groups as at least, 2.1 and, more preferably, as at least, 2.5. Mixed molecules derive mixed cross-link polymers when contacting to organism tissues with water added. Cross-link polymer framework with is biologically compatible and biologically decomposable. Cross-link polymer framework is decomposed to products including molecules and precursors with number of functional amides.

EFFECT: improved adhesive and agglutination method.

20 cl, 4 dwg, 10 ex

FIELD: medicine.

SUBSTANCE: invention describes a glue composition contacting skin, with improved original and lasting adhesion properties, water absorption and light permeability, which can be obtained by a melt extrusion. The compositions can be applied in wound dressing.

EFFECT: improved composition.

97 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine. What is described is a composition for hard tissue repair containing 5 to 98.95 weight portions of a monomer (A), 1 to 75 weight portions of (meth)acrylate polymer (B) and 0.05 to 20 weight portions of a polymerisation initiating composition (C) containing an organoboron compound (c1) providing the ingredients (A), (B) and (C) total makes 100 weight portions. What is described is a kit for the hard tissue repair.

EFFECT: composition generates little setting heat and can provide for manipulations for a long period of time.

18 cl, 2 dwg, 11 tbl

Antimicrobial gels // 2535013

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to medicine, particularly to aspects covering antimicrobial compositions, and described antimicrobial compositions, antimicrobial silicone gel based on the above antimicrobial composition, a wound dressing and methods for preparing them. Among other things, the antimicrobial compositions contain at least one alkenyl- and/or alkynyl-substituted polysiloxane, at least one polysiloxane containing silicone-linked hydrogen atoms, and at least one hydroxylation catalyst, at least one hydrophilic ingredient, at least one silver salt.

EFFECT: invention can be used for preparing a drug preparation to be used in treating burns, scars, bacterial infections, viral infections and/or mycotic infections.

19 cl, 5 dwg, 8 ex, 6 tbl

FIELD: medicine.

SUBSTANCE: what is described is a non-woven fabric consisting of several layers and comprises spot-glued carrier with polyamide nanofibres containing at least one antimicrobial substance, and a protecting coat. The polyamide nanofibres are made of polyamide and can be fixed on the carrier by means of a liquid adhesive. Non-woven fibre fabrics of the density of 15 to 90 g/m2 are used as the carrier of the nanofibres and protecting coat: polypropylene, polyester, cellulose-polyester, cellulose or paper. The polyamine nanofibres contain at least one antimicrobial substance in an amount of 0.4 to 35% of nanofibre weight among: guanidines, metal nanoparticles, stabilised silver salts, quaternary ammonium compound salts.

EFFECT: material possesses antimicrobial activity, high air permeability, and fracture resistance.

9 cl, 2 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: what is described is hydrogel composition containing sodium acrylate, a linking agent, biologically active substances, polyvinyl pyrrolidone, glycerol, propanediol, water, a catalyst agent and a radical polymerisation indicator in the following proportions, wt %: sodium acrylate 2.0-10.0, catalyst agent 0.045-0.48, linking agent 0.195-0.21, radical polymerisation indicator 0.045-0.06, glycerol 4.5-7.5, propanediol 3.0-10.5, biologically active substances 0-1.5, polyvinyl pyrrolidone 0.3-1.5, water - the rest. What is described is a surgical dressing containing a carrier with the hydrogel composition applied thereon.

EFFECT: higher efficacy of the hydrogel composition and surgical dressing thereof, lower labour intensity of the method for preparing the above composition.

10 cl, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of obtaining and production of filtering materials for purification of air of industrial premises based on polymer fibres, possessing antibiotic properties. Synthesis of a polymer on a filtering material in low-temperature glow discharge plasma in adamantane vapours is performed. First, a chamber with the filtering material is vacuumed, argon is supplied and gas discharge purification of material is carried out. After purification the chamber is re-vacuumed and vapours of adamantane are input with further ignition of the glow discharge to obtain a thin coating on the material surface.

EFFECT: invention makes it possible to render antibiotic (antifungal) properties to the surface of the filtering material.

1 ex

FIELD: medicine.

SUBSTANCE: dressing represents a knitted mesh fabric coated with a composition of a biocompatible film-forming polymer of polyvinyl pyrrylidone and drug preparations: iodine, novociane, carboxymethyl cellulose sodium salt, of the following formulation (mg/cm2): iodine 0.0282±20%; polyvinyl pyrrylidone (Mr 20000) 1.2±20%; novociane 0.426±20%; carboxymethyl cellulose sodium salt 1.6-1.9.

EFFECT: using the wipe provides antimicrobial, antiseptic, disinfecting, antifungal and antiprotozoal action ensured by the fact that a polyvinyl pyrrylidone matrix retains iodine in the wipe and promotes its release on the skin.

FIELD: medicine.

SUBSTANCE: agent contains chitosan salt 75-95 wt % of polydisperse powders of chitosan hydrochloride, hydrobromide, formate, acetate, succinate, citrate, glycolate or lactate and polyhexamethylene guanidine hydrochloride 4-20 wt %. The chitosan salt and polyhexamethylene guanidine hydrochloride are covalently cross-linked by a polyfunctional compound 1-5 wt % of glycidyl ethers. The chitosan salt is specified with an average particle size of 0.2÷2.0 mm, degree of chitosan deacetylation 0.75÷0.95, and molecular weight 10÷500 kDa. The above polyfunctional compound of glycidyl ethers is presented by a diglycidyl ether of butandiol, di- or triethylene glycol or propylene glycol, oligoethylene oxide, as well as triglycidyl ethers of glycerol or trimethylol propane.

EFFECT: method possesses high blood sorption capacity, rapid hemostasis time and high antimicrobial activity.

3 cl, 2 tbl, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and medical equipment and may be used in preparing multifunctional biological active structures for the fixation of dressings and objects. The fixation device consists of a paper carrier made of cellulose and viscous fibres impregnated with a special preparation, dried; with its one side of the prepared carrier coated with an adhesive and with its other side coated with a primer and an adhesive.

EFFECT: improved drape effect, enhancement, easier and faster usage.

6 cl, 1 tbl, 2 ex

Wound dressing ii // 2508127

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, more specifically to a sterile wound dressing having a bearing surface and a non-absorbent elastomeric layer contacting the wound; an elastomeric matrix comprises a synthetic three-unit elastomer, preferentially a polystyrene and polyolefin copolymer (SEPS, SEBS, SEEPS, etc.), or a mixture thereof; the total content of the polymer makes less than 3.2 wt %, particularly 3.0 wt % or less, preferentially 2.6 wt % or less, and plasticised by a non-polar oil and/or vaseline.

EFFECT: wound dressing provides better tissue compatibility.

12 cl, 1 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine. What is described is a superabsorbent polymer composite containing superabsorbent polymers and cellulose nanofibrils having a diameter of 100 nm or less. The composite may be presented in the form of either particles, or foam. There are also described methods for preparing the composite and absorbent products containing the superabsorbent polymer composite.

EFFECT: cellulose nanofibrils improve the gel strength of the superabsorbent polymer.

23 cl, 6 dwg, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine. What is described is a composition for hard tissue repair containing 5 to 98.95 weight portions of a monomer (A), 1 to 75 weight portions of (meth)acrylate polymer (B) and 0.05 to 20 weight portions of a polymerisation initiating composition (C) containing an organoboron compound (c1) providing the ingredients (A), (B) and (C) total makes 100 weight portions. What is described is a kit for the hard tissue repair.

EFFECT: composition generates little setting heat and can provide for manipulations for a long period of time.

18 cl, 2 dwg, 11 tbl

Up!